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ABSTRACT
SIGNALING MECHANISMS IN REGENERATIVE MYOGENESIS
Sajedah M. Hindi
November 25, 2014

Skeletal muscle constitutes a highly plastic and malleable tissue that rapidly and profoundly
adapts to various environmental and physiological stimuli. This response takes place by
means of regulated signaling transduction which elicits changes in gene expression,
biochemical, and metabolic properties. Adult muscle is composed by alignment of multinucleated, post mitotic muscle fibers formed during embryonic and neonatal development.
Residing in the niche of mature muscle fibers is a small population of undifferentiated
muscle progenitors termed satellite cells. Satellite cells are muscle stem cells that carry out
regenerative response in adult myofibers. Coordinated signaling emitting from terminally
differentiated muscle fibers and un-differentiated muscle progenitors sustains muscle
homeostasis. De-regulation in the components of this synchronized signaling machinery
manifests in deleterious disease states and myopathies.
The main focus of my research has been towards understanding the role of the
adaptor protein, tumor necrosis factor-associated factor 6 (TRAF6) in regulation of
regenerative myogenesis. Utilizing the Cre-loxP system, we generated TRAF6 musclespecific knock-out mice: TRAF6mko, and TRAF6 satellite cell-specific knock-out mice:
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TRAF6scko. Our findings displayed distinct roles of TRAF6 in differentiated
myofibers vs. satellite cells. Deletion of TRAF6 under the control of muscle creatine kinase
(MCK) promoter (differentiated muscle) led to improvement in muscle regeneration in wildtype (WT) mice following induced muscle injury. This improvement was brought about by
prevalence of an anti-inflammatory environment characterized by reduced signaling from
inflammatory pathways such as NF-B and a domination of pro-regeneration M2c over proinflammatory M1 macrophages. Regenerating muscle of TRAF6mko mice also displayed a
higher up-regulation in Notch signaling family proteins and target genes which in turn
enhanced the activation of satellite cells leading to accelerated regeneration. Similar results
were also observed upon deletion of TRAF6 in differentiated muscle of mdx mice (model
for Duchenne muscular dystrophy). However, mdx;TRAF6mko muscle later displayed
exacerbated signs of myopathy possibly due to diminished autophagy which has been
associated with progressive myopathy in mdx mice.
Employing the same models of muscle injury, our analysis revealed an absolute
requirement of TRAF6 in satellite cell function during regenerative myogenesis. Contrary to
its role in differentiated muscle, injured muscle of TRAF6scko mice displayed impaired
regeneration due to a cell-autonomous defect in TRAF6-deficient satellite cells. Deletion of
TRAF6 in satellite cells dramatically repressed the levels of Pax7 resulting in precocious
differentiation and progressive depletion of the satellite cell reservoir. Myopathy was further
exaggerated in dystrophic muscle of mdx;TRAF6scko due to satellite cell dysfunction. Our
results further demonstrate that TRAF6 regulates proliferation and self-renewal of satellite
cells through activation of mitogen-activated protein kinases (MAPKs) such as ERK1/2 and
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JNK and through modulating the levels of muscle specific microRNA’s: miR-1, miR-206,
and mir-133a.
The findings of this work highlight the importance of implementing a holistic
approach upon development of target-based therapies. Oversight of the fundamental roles of
targeted molecules has been associated with virulent outcomes. Developing a universal
understanding of the various implications of individual molecules maximizes therapeutic
potential.
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CHAPTER 1

GENERAL INTRODUCTION
1.1 Skeletal muscle regeneration. Skeletal muscle constitutes the most abundant tissue in
the mammalian organ system. The genesis of muscle transpires through a series of
molecular events that follow precise temporal and spatial regulation (1, 2). During
embryogenesis, proliferating mesodermal myoblasts are directed to align at juxtapose of one
another. Molecular and mechanical cues provoke rearrangement of actin cytoskeleton at
contact sites allowing for membrane-membrane fusion and myofiber formation. In
resolution of embryonic development, a fraction of undifferentiated muscle precursor cells
exit the cell cycle and inhabit the muscle niche in a sub-mitotic and -metabolic state.
Characterized as “satellite” by their sublaminar localization and intimate association with
the myomembrane, satellite cells compose the major adult stem cell population of skeletal
muscle. At neonatal age, satellite cells compromise 30% of myonuclei in mouse skeletal
muscle. However, this percentage sharply declines to reach 4% at adulthood and 2% in
aging mice (1-4). High adaptability of skeletal muscle is owed in large to the remarkable
regenerative capacity of satellite cells. When activated by stimuli such as muscle injury or
exercise, satellite cells begin to proliferate and commit to a myoblast cell fate, characterized
by the expression of certain myogenic regulatory factors (MRFs) and lineage markers, such
as Myf5, MyoD and α7-integrin, and in resolution, exit the cell cycle to either terminally
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differentiate and fuse to form nascent myotubes or self-renew and return back to quiescence
to replenish the satellite cell pool to participate in next rounds of regeneration. Impairment
in the process of myogenesis contributes significantly to loss of skeletal muscle mass in
many disease conditions. A better understanding of the process of skeletal muscle
regeneration is required not only to improve muscle repair but also to develop better stemcell based therapies for treatment of genetic muscular diseases (1-4).

1.2 Muscular dystrophy. Muscular dystrophy comprises a group of genetic diseases that
cause progressive degeneration of skeletal muscle fibers resulting in severe pain, disability,
and eventually death (5). The primary cause for various forms of muscular dystrophies is the
mutations in individual genes that encode a wide variety of proteins, including extracellular
matrix (ECM) proteins, transmembrane and membrane-associated proteins, cytoplasmic
enzymes, and nuclear matrix proteins (6, 7). However, the most severe forms of muscular
dystrophies occur due to mutations in the components of the dystrophin-glycoprotein
complex (DGC), a molecular scaffold which is localized to sarcolemma and provides
mechanical stability to striated muscle. For example, mutations in dystrophin or any of the
sarcoglycans leads to destabilization of sarcolemma (i.e. muscle membrane) and a
dystrophic phenotype.
Duchenne muscular dystrophy (DMD) is one of the most prevalent forms of
muscular dystrophies that results from total or partial deficiency of functional dystrophin
protein (Figure 1.1). Dystrophin is a critical component of DGC, which links the
cytoskeleton of the muscle fibers to the ECM (8). Dystrophin has also been suggested as an
important cytolinker that stabilizes cells by linking actin filaments, intermediate filaments,
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and microtubules to transmembrane complexes (9). In the absence of dystrophin, the DGC is
functionally impaired and the mechanical stress associated with muscle contraction leads to
sarcolemmal damage and fiber necrosis (10, 11). While mechanical injury and sarcolemmal
defects are important triggering mechanisms promoting dystrophic phenotype, neither fully
explains the onset of DMD or its progression. Studies in animal models and humans have
shown that partial or complete loss of DGC proteins results in the activation of several
pathological cascades which aggravate disease progression (10, 12-15).
Besides acting as a molecular scaffold serving mechanical function, DGC also has an
important signaling role in striated muscle. Loss of dystrophin in skeletal muscle leads to
aberrant activation of a number of signaling pathways such as nuclear factor-B (NF-B),
phosphatidyl inositol 3-kinase (PI3K)/Akt, and mitogen-activated protein kinases (MAPKs)
(16-21). Intriguingly, many signaling pathways that have been found to be involved in
pathogenesis of muscular dystrophy are activated before the onset of fiber necrosis
signifying that loss of functional DGC is sufficient to disrupt physiological signaling in
striated muscle (17). Furthermore, abnormal myogenic signaling has also been reported in
other forms of muscular dystrophies that result from loss of nuclear membrane protein (e.g.
lamins A/C, Emerin) or cytoplasmic enzymes (e.g. calpain-3) suggesting that signaling
defects is a common pathological mechanism in all types of muscular dystrophies (17).
Because activation of different signaling cascades results in altered gene expression,
aberrant myogenic signaling could be critical for the onset and perpetuation of pathology in
muscular dystrophy.
Although the long term studies covering the entire life-span of the animals are yet to
be performed, several studies have shown that the inhibition of MAPK or NF-B signaling

3

pathways using molecular and pharmacological approaches improves muscle pathology in
animal models of DMD (16-18, 20, 21). However, given the progressive degenerative nature
of DMD and the convoluted involvement of many secondary processes, developing a pan
therapeutic strategy that proves beneficial during the course of the disease has been
challenging. Indeed, recent studies have provided evidence that combinatorial approaches
which involve simultaneous intonation of multiple pathological pathways would be more
effective therapies for DMD (17, 22-24). While it is clear that pathogenesis of muscular
dystrophy involves aberrant activation of multiple signaling pathways, it remains unknown
whether they are activated through upstream activation of a common signaling network or
they are independently regulated.
1.3 TRAF6 signaling. TRAF family is a group of seven adaptor proteins (TRAF1-TRAF7)
that link a wide variety of cell surface receptors to the intracellular signaling proteins (25).
TRAF6 has several distinct features that are not shared by other members of the family (26,
27). TRAF6 (along with TRAF2) is an important E3 ubiquitin ligase. The N-terminal RING
domain of TRAF6 is required for its ability to transmit signal, by functioning as an E3
ubiquitin ligase, which together with the ubiquitin conjugating enzyme complex
Ubc13/Uev1A catalyzes the synthesis of a unique polyubiquitin chain linked through lysine63 (K63) residue in ubiquitin (28, 29). This unique ubiquitin modification does not target
TRAF6 for degradation, but rather the auto-ubiquitination of TRAF6 serves as a scaffold to
recruit molecules essential for downstream activation of various signaling pathways (Figure
1.2) (30-34). Studies in the recent past have established that TRAF6 is central to the
activation of many signaling pathways including NF-B, MAPK, and PI3K/Akt in response
to cytokines and microbial products (29, 33-36). Of note is the discovery that among all
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known TRAFs, only TRAF6 interacts with scaffold protein p62/Sequestosome1 which is
involved in regulation of autophagy and TRAFficking of ubiquitinated (Ub K48-linked)
proteins to the proteasome (37-40). More recently, it has been found that TRAF6 promotes
the Lys-63-linked ubiquitination of Beclin1, which is critical for the induction of autophagy,
in response to Toll-like receptor 4 (TLR4) signaling. While the role of TRAFs in tissue
destruction and cell death in several other diseases has been studied, how TRAFs regulates
muscle regeneration in normal and diseased muscle and the role of TRAF6 in myogenesis
was not previously studied. My dissertation is focused to understanding the role of TRAF6
in regenerative myogenesis.

1.4 TRAF6 signaling in skeletal muscle atrophy. Skeletal muscle atrophy has been
explored extensively over the last decade. Many of these studies were aimed to unearth the
mechanisms that orchestrate catabolic changes in an atrophic program. Expression and
activation of E3 ubiquitin ligases, MuRF1, and Atrogin-1, has been suggested to be at the
distal end of several catabolic pathways and biochemical changes observed in atrophying
skeletal muscle. TRAF6, being a different type of E3 ubiquitin-ligase, may not be directly
involved in targeting myofibrillar proteins for degradation, however, it can potentially be an
upstream regulator for the activation of signaling cascades that eventually lead to loss of
muscle proteins in conditions of atrophy. Our group has done the pioneer work towards
understanding the role of TRAF6 in skeletal muscle atrophy. We have reported that TRAF6
is the only TRAF that is regulated through myogenic differentiation (41, 42). The levels of
TRAF6 are also significantly induced in skeletal muscle in response to denervation, tumorinduction, or diabetes onset (41). More recent findings in our laboratory have suggested that
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the levels and autoubiquitination of TRAF6 are also increased in skeletal muscle of mice in
response to fasting (43).
A previous graduate student (Dr. Pradyut K. Paul) in our laboratory evaluated the
role of TRAF6 in skeletal muscle atrophy using muscle-specific TRAF6-knockout
(TRAF6mko) mice. While previous studies have shown that TRAF6-null mice show
significant abnormalities and are perinatally lethal (44, 45), there was no overt phenotype
upon depletion of TRAF6 only in skeletal muscle of mice (41). Remarkably, the hallmark
signatures of atrophy such as loss of skeletal muscle mass, specific muscle proteins, fiber
cross section area, and contractile force production were significantly rescued in TRAF6mko
mice compared to littermate control mice in two distinct models of atrophy: denervation and
cancer cachexia (41). Skeletal muscle of TRAF6mko mice also demonstrated reduced
activation of UPS and expression of MuRF1 and MAFBx compared to control TRAF6f/f
mice in atrophic conditions [16]. The reduced expression of MuRF1 and MAFBx could be a
result of inhibition of catabolic pathways and transcription as muscle specific ablation of
TRAF6 was sufficient to inhibit the activation of NF-κB, AMPK, JNK, and p38 MAPK
pathways [16]. It is already known that TRAF6 interacts with p62/SQSTM1-LC3 and
Beclin-1 which are markers of autophagy (46). Recapitulating this in skeletal muscle, we
observed not only a significant reduction in the expression of components of ALS but also
reduced autophagosome formation and mitochondrial degradation [16].
Extending this quest further, our laboratory has investigated the role of TRAF6 in
starvation-induced skeletal muscle atrophy. Surprisingly, it was observed that TRAF6
regulates different atrophic programs by employing distinct mechanisms. In addition to UPS
and ALS, nutrient deprivation also induced the expression and activation of several

6

components of endoplasmic reticulum (ER) stress and unfolded protein response (UPR)
(43). There was no previous evidence that TRAF6 has any interaction with components of
UPR. We have shown that both TRAF6mko mice and TRAF6-deficient mouse embryonic
fibroblasts (MEFs) exhibit significantly reduced activation of ER-stress and UPR markers in
response to starvation (43).
It is notable that while depletion of TRAF6 significantly inhibits muscle atrophy and
activation of catabolic pathways in response to both cancer cachexia and denervation, the
effect is more pronounced in cancer cachexia (41). Better rescuing effect of inhibition of
TRAF6 in cancer cachexia model could be attributed to the fact that muscle wasting in
tumor-bearing subjects involves systemic inflammation evident by increased levels of
catabolic cytokines and fibrosis (47). A plethora of literature exists suggesting that several
proinflammatory cytokines and tumor-derived factors require TRAF6 for downstream
activation of NF-κB and MAPK signaling pathways which are also known to mediate
skeletal muscle atrophy (27, 48, 49). By contrast, inflammatory response is not very
common in denervated skeletal muscle though TWEAK cytokine has now been found to be
an important mediator of muscle loss under conditions of denervation (50, 51). However, the
denervation-induced muscle loss was also not completely blunted in TWEAK-KO mice (50)
suggesting that muscle atrophy in response to denervation involves some other unidentified
factor(s) that function independent of TRAF6.
Earlier research has established diversified regulatory roles of TRAF6 in several
systems. Findings from our group extended this further to skeletal muscle atrophy and adds
novel information by demonstrating that TRAF6 augments skeletal muscle atrophy through
activation of several distinct mechanisms (41). Although this information underlines a new
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potential of TRAF6 as a therapeutic target, the regulation of TRAF6 itself is not yet fully
delineated. Future research will unveil the mechanisms leading to increased expression of
TRAF6 in atrophying muscle and how TRAF6 mediates muscle atrophy in response to
diverse stimuli.

1.5 Role of TRAF6 in differentiated myofibers vs. muscle progenitor cells during
regenerative myogenesis. TRAF6 is highly expressed in proliferating myoblast and skeletal
muscle of neonatal mice, however, its expression is sharply reduced upon terminal
differentiation of myotubes and completion of development in skeletal muscle (41).
Interestingly, the expression of TRAF6 re-emerges in adult skeletal muscle in response to
catabolic stimuli and muscle injury. Regulated expression of TRAF6 during myogenesis and
re-expression in response to triggering stimuli implies a complex role of TRAF6 in
regulating myogenesis. Experiments conducted throughout this study aim at dissecting the
functional outcome of TRAF6 signaling at various stages of regenerative myogenesis and a
disease model.
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FIGURE 1.1

FIGURE 1.1. Genetic basis of Duchenne muscular dystrophy
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FIGURE 1.2

FIGURE 1.2. TRAF6-mediated regulation of signaling pathways
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CHAPTER 2
RECIPROCAL INTERACTION BETWEEN TRAF6 AND NOTCH
SIGNALING REGULATES ADULT MYOFIBER REGENERATION UPON
INJURY
2.1 INTRODUCTION
Skeletal muscle regeneration following injury is facilitated by a population of
undifferentiated muscle precursor cells, commonly referred to as satellite cells (3). Satellite
cells reside between the plasma membrane and basal lamina in a relatively quiescent state
and with diminished metabolic activity (1, 52). Quiescent satellite cells express cell surface
markers such as CD34, M-cadherin and Pax7 (53). When activated by stimuli such as
muscle injury or exercise, satellite cells begin to proliferate and commit to a myoblast cell
fate, characterized by the expression of certain myogenic regulatory factors (MRFs) and
lineage markers, such as Myf5, MyoD and 7 integrin, and in resolution exit the cell cycle
to either terminally differentiate and fuse to form nascent myotubes or self-renew and return
back to quiescence to replenish the satellite cell pool to participate in next rounds of
regeneration (1).
Myofiber regeneration is dynamically regulated by signals released from both the
damaged/regenerating muscle as well as other cell types either resident in the muscle or
recruited to assist in clearing the damaged myofibers (3, 54, 55). Although considerable
progress has now been made to understanding the mechanisms of muscle regeneration, the
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proximal signaling events leading to the activation of various signal pathways in
regenerating myofibers remain poorly understood. Tumor necrosis factor (TNF) receptorassociated factors (TRAFs) are a family of conserved adaptor proteins which act as signaling
intermediates for TNF receptor superfamily members and several other receptor-mediated
events leading to context-dependent activation of nuclear factor-kappa B (NF-B),
phosphatidylinositol 3-kinase (PI3K)/Akt, and MAPK (27, 48). Distinct from other TRAFs,
TRAF2 and TRAF6 are also E3 ubiquitin ligases which promote Lys63-linked polyubiquitination of target proteins (33). TRAF6 is unique because it is the only TRAF that
mediates toll-like receptor (TLR)/interleukin-1 receptor (IL-1R) superfamily signaling (27).
Interestingly, the expression of TRAF6 (but not other TRAFs) is highly regulated in C2C12
myoblasts. Proliferating myoblasts and skeletal muscle of neonatal mice express high levels
of TRAF6. However, the expression of TRAF6 is considerably reduced upon their
differentiation into myotubes (41). Importantly, the levels of TRAF6 are increased in
differentiated myofibers in response to catabolic stimuli and TRAF6 mediates skeletal
muscle wasting in multiple catabolic conditions (41, 43). However, the role of TRAF6 in
satellite cell activation and adult myofiber regeneration remains completely unknown.
Notch is a key signaling pathway involved in embryonic myogenesis and in
regulating events that lead to regeneration of adult skeletal muscle (56, 57). Notch signaling
is initiated when a Notch ligand such as Jagged1, Jagged2, Delta-like 1 (DLL1), DLL3 or
DLL4 binds to a transmembrane cell surface Notch receptor (Notch1-4) on the neighboring
cell (58). These ligand-receptor interactions lead to proteolytic cleavage of the Notch
receptors via the -secretase complex, releasing the Notch intracellular domain (NICD),
which translocates to the nucleus and binds the transcriptional repressor, RBP-J, converting
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it into an activator and inducing the expression of downstream target genes (58, 59). Some
of the most well-defined RBP-J-dependent, Notch target genes include specific members
of the Hes/Hey family of basic helix-loop-helix transcription factors: Hes1, Hes5, Hes7,
Hey1, Hey2 and HeyL which encode basic helix-loop-helix (bHLH) transcriptional
repressors that specifically bind to E-box (CANNTG) DNA sequences (60, 61) and mediate
much of Notch function (62). In addition, Notch-regulated ankyrin repeat protein (Nrarp)
has also been shown to be a target of Notch signaling (63).
Notch regulates proliferation and commitment of activated satellite cells to myogenic
lineage. Activation of Notch signaling is a prerequisite for the expansion of postnatal
satellite cells and to prevent the premature differentiation of myogenic precursors in injured
myofibers (3, 57, 64-69). Age-associated decline in satellite cells proliferative capacity is
attributed, at least in part, to the insufficient up-regulation of Notch ligand DLL and hence
reduced activation of Notch leading to impaired muscle regeneration (65). The critical role
of Notch in muscle regeneration has been validated by the findings that the forced activation
of Notch restored the regenerative potential of aged skeletal muscle (65), an outcome
recapitulated by exposure of aged regenerating muscle to serum from young animals (70).
Notch signaling is also essential for asymmetric satellite cell division and for progression of
cultured myoblasts through cell cycle (64, 67, 71). Recently, it has been shown that basal
level of Notch activity is required for maintenance of satellite cells in undifferentiated state
(72-74). Furthermore, Notch3 is highly expressed in a subpopulation of quiescent satellite
cells (64, 75) indicating that Notch signaling may underlie the heterogeneity of satellite
cells.
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In contrast to Notch, the activation of nuclear factor-kappa B (NF-κB) signaling
pathway has been found to inhibit the differentiation of cultured myoblasts (76, 77) and
attenuates the regeneration of adult myofibers upon injury (78). Activation of NF-B causes
the expression of a number of proinflammatory molecules such as TNF-α and IL-1β which
function by directly inhibiting differentiation of muscle progenitor cells (77). Cross-talk
between NF-B and Notch pathways has been implicated in regulating multiple cellular
events such as proliferation, differentiation, and apoptosis. Previous studies have shown that
NICD can modulate NF-B-regulated promoters both positively, by sequestering RBPJ (79,
80) or negatively, by interacting with the p50 subunit of NF-B (80). It has been suggested
that NICD functions as IκB-like molecule and regulates NF-κB-mediated gene expression
through a direct interaction with the p50 subunit of NF-B (80). This interaction prevents
binding of NF-B to DNA to regulate NF-κB-dependent gene expression (80). However, such
interplay between Notch and NF-B has not been yet characterized in the settings of skeletal
muscle regeneration. It is also unclear whether there is a common denominator that controls
the activation of these two signaling pathways in regenerating myofibers.

Using skeletal muscle-specific TRAF6-knockout mice, in the present study, we have
investigated the role and the mechanisms by which TRAF6 regulates regeneration of adult
skeletal muscle. Our study provides initial evidence that the ablation of TRAF6 dramatically
improves myofiber regeneration upon injury. Inhibition of TRAF6 augments the expression
of Notch ligands in injured myofibers leading to the activation of satellite cells in a Notchdependent manner. Moreover, inhibition of TRAF6 attenuates activation of NF-B and
expression of inflammatory cytokines in injured skeletal muscle.
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2.2 MATERIALS AND METHODS
Animals. Generation of transgenic floxed TRAF6 (TRAF6f/f) and muscle specific knock-out
for TRAF6 (TRAF6mko) mice have been described previously (41, 81). All mice were in the
C57BL6 background and their genotype was determined by PCR from tail DNA. At the age
of 8 weeks, 100 µl of 10 µM cardiotoxin (Sigma Chemical Co.) dissolved in phosphatebuffered saline (PBS) was injected into the TA muscle to induce necrotic injury. At various
time points, TA muscle was collected from euthanized mice for biochemical and histology
studies. All experimental protocols with mice were approved by the Institutional Animal
Care and Use Committee at University of Louisville.

Histology and Morphometric Analysis. Hind limb muscle from mice were isolated and
frozen in isopentane cooled in liquid nitrogen and sectioned in a microtome cryostat. For the
assessment of tissue morphology or visualization of fibrosis, 10-µm-thick transverse
sections of muscles were stained respectively with the Hematoxylin and Eosin (H&E) and
examined under Nikon Eclipse TE 2000-U microscope (Nikon). Fiber cross-sectional area
was analyzed in H&E-stained TA muscle sections using Nikon NIS Elements BR 3.00
software (Nikon). For each muscle, the distribution of fiber cross-sectional area (CSA) was
calculated by analyzing 200 to 250 myofibers as described (41). The extent of fibrosis in
transverse cryosections of TA muscle determined using Masson’s Trichrome staining kit
following a protocol suggested by the manufacturer (Richard-Allan Scientific).
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Electroporation of plasmid DNA in TA muscle: The injection of plasmid DNA into TA
muscle of mice and electroporation were performed according to a protocol as described
(41, 50). In brief, pcDNA3 and pcDNA3-TRAF6 plasmids were amplified using an
endotoxin-free kit (QIAGEN) and suspended in sterile saline solution. Mice were
anesthetized, and a small portion of TA muscle of both hind limbs was surgically exposed
and injected with 30 µl of 0.5 U/µl hyaluronidase (EMD Biosciences). After 2 h, plasmid
DNA (50 µg in 25 µl saline) was injected in TA muscle using 26 gauge needle, and 1 min
later a pair of platinum plate electrodes was placed against the closely shaved skin on either
side of the small surgical incision, and electric pulses were delivered. Four 20-ms squarewave pulses of 1-Hz frequency at 75V/cm were generated using a stimulator (Model S88;
Grass Technologies) and delivered to the muscle. The polarity was then reversed, and a
further three pulses were delivered to the muscle. After electroporation, the wound was
closed with surgical clips, and mice were returned to their cages and fed a standard diet.

Indirect Immunofluorescence: For immunohistochemistry study, TA muscle section
sections or paraformaldehyde-fixed cultured myotubes were blocked in 1% bovine serum
albumin in PBS for 1h, and incubated with anti-Pax7 (1:20, Developmental Studies
Hybridoma Bank, University of Iowa, Iowa City, IA), anti-E-MyHC (1:50, Developmental
Studies Hybridoma Bank, University of Iowa, Iowa City, IA), anti-MF20 (1:250,
Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA) or antiJagged2 (1:100, SantaCruz Biotechnology) in blocking solution at 4C overnight under
humidified conditions. The sections were washed briefly with PBS before incubation with
Alexa Fluor® 488 or 594-conjugated secondary antibody (1:3000, Invitrogen) for 1h at
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room temperature and then washed 3 times for 30 minutes with PBS. The slides were
mounted using fluorescence medium (Vector Laboratories) and visualized at room
temperature on Nikon Eclipse TE 2000-U microscope (Nikon), a digital camera (Nikon
Digital Sight DS-Fi1), and Nikon NIS Elements BR 3.00 software (Nikon). Image levels
were equally adjusted using Abode Photoshop CS2 software (Adobe).

Isolation, Culture, and Staining of Single Myofibers. Single myofibers were isolated from
the extensor digitorum longus (EDL) muscles after digestion with collagenase A (Sigma)
and trituration as previously described. Suspended fibers were cultured in 60-mm horse
serum-coated plates in Dulbecco's modified Eagle's medium supplemented with 10% fetal
bovine serum (FBS; Invitrogen), 2% chicken embryo extract (Accurate Chemical, Westbury,
NY), and 1% penicillin-streptomycin for 3 days. Freshly isolated fibers and cultured fibers
were then fixed in 4% PFA and stained for Pax7, MyoD, Ki67, or Jagged2 as described (82).
To study the role of Notch signaling, myofibers were treated with 10µM DAPT after 24h of
establishing cultures.

Western Blot. Quantitative estimation of specific protein was performed by Western blot
using a method as described (41, 50). TA muscle were washed with PBS and homogenized
in lysis buffer [50 mM Tris-Cl (pH 8.0), 200 mM NaCl, 50 mM NaF, 1 mM dithiotheritol
(DTT), 1 mM sodium orthovanadate, 0.3% IGEPAL, and protease inhibitors].
Approximately, 100 μg protein was resolved on each lane on 8-10 % SDS-PAGE,
electrotransferred onto nitrocellulose membrane and probed using anti-MF20 or anti-EMyHC (1:100, Developmental Studies Hybridoma Bank), anti-TRAF6(1:1000, Millipore),
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anti-phospho-Akt (1:1000, Cell Signaling, Inc), anti-total Akt (1:1000, Cell Signaling, Inc),
anti-phospho p38 (1:1000, Cell Signaling, Inc), anti-total p38 (1:1000, Cell Signaling, Inc.),
and anti-α-tubulin (1:2000, Cell Signaling, Inc.) and detected by chemiluminescence.

Fluorescence Activated Cell Sorting (FACS). Activated satellite cells and M1 and M2c
macrophages were analyzed by FACS as described (64, 83). Approximately 2x106 cells
were incubated in DMEM (supplemented with 2% FBS and 25 mM 4-(2-hydroxyethyl)-1piperazineethanesulfonic acid)) and dead cells (positive for Propidium iodide staining)
which were around ~1% were excluded from all FACS analysis. For satellite cell
quantification from heterogeneous cell population, cells were immunostained with
antibodies against, CD45, CD31, CD56/Sca-1, and Ter-119 for negative selection (all PE
conjugated, eBiosciences), and with α7β1-integrin (MBL International) for positive
selection. A tandem conjugate of R-PE (Alexa 647, Molecular Probes) was used as a
secondary antibody against α7β1-integrin. Macrophages were quantified from
heterogeneous cell population by selection of F4/80+ (PerCP Cy5.5-conjugated,
eBiosciences) cells against negative selection by CD56/Sca-1, CD140a and Ter-119 (all PEconjugated, eBiosciences). From F4/80+ cells, CD11c+ (APC-conjugated, eBiosciences) M1
and CD206+ (FITC-conjugated, Biolegend) M2c macrophages were isolated. FACS analysis
was performed on a C6 Accuri cytometer equipped with three lasers. The output data was
processed and plots were prepared using FCS Express 4 RUO software (De Novo Software).

Electrophoretic Mobility Shift Assay (EMSA). DNA-binding of NF-B was measured by
performing EMSA as previously detailed (41). In brief, 20 µg of nuclear extracts prepared
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from control or CTX-injected TA muscle were incubated with 16 fmol of 32P end-labeled
NF-B consensus oligonucleotide (Promega) at 37 °C for 30 min, and the DNA-protein
complex was resolved on a 7.5% native polyacrylamide gel. The radioactive bands from the
dried gel were visualized and quantified by PhosphorImager (GE Health Care) using
ImageQuant TL software.

RNA Isolation and Quantitative Real-time PCR (QRT-PCR). RNA isolation and QRTPCR were performed using a method as previously described (41). The sequence of the
primers is described in Table 2.1.

Statistical Analyses. Results are expressed as mean ± standard deviation (SD). Statistical
analyses used Student's t-test to compare quantitative data populations with normal
distribution and equal variance. A value of P < 0.05 was considered statistically significant
unless otherwise specified.

2.3 RESULTS
(Note: Some of the experiment on this part of the project were done by a previous graduate
student, Pradyut K Paul as a part of his dissertation. I carried on with the project and
performed a vast number of experiments to complete this study. I have not included any of
his data in this chapter but referred to our joint first author publication for the results
exclusively performed by Pradyut K. Paul (84)).

19

2.3.1 Targeted deletion of TRAF6 improves myofiber regeneration in response to
injury. An acute injury to skeletal muscle is followed by a well-orchestrated series of events
which facilitate rapid repair and regeneration of injured muscle (1, 4). We first investigated
how the expression of TRAF6 is affected in skeletal muscle in response to injury. Wild-type
mice were given intramuscular injection of saline alone or cardiotoxin (CTX) in the tibial
anterior (TA) muscle. Western blot analysis showed that the levels of TRAF6 protein
dramatically induced in CTX-injected TA muscle at 5d post injury (Figure 1A). The
increased levels of TRAF6 protein was potentially due to its increased transcription because
mRNA levels of TRAF6 were also found to be significantly increased in CTX-injected TA
muscle compared to contralateral muscle injected with saline alone (please refer to (84)).
We next sought to determine the role of TRAF6 in skeletal muscle regeneration. To
specifically delete TRAF6 in differentiated myofibers, floxed TRAF6 (TRAF6f/f) mice were
crossed with muscle creatine kinase (MCK)-Cre mice to obtain muscle-specific TRAF6knockout (henceforth TRAF6mko) mice as previously detailed (41). The levels of TRAF6
protein (but not other TRAFs) are considerably reduced specifically in skeletal muscle of
TRAF6mko mice compared to littermate TRAF6f/f mice (41). Satellite cells prepared from
TRAF6f/f and TRAF6mko mice showed no difference in the protein levels of TRAF6 (Figure
2.1) suggesting that TRAF6 protein is reduced in differentiated myofibers but not in muscle
progenitor cells of TRAF6mko mice. TA muscle of 8-week old TRAF6mko and its littermate
TRAF6f/f mice were given intramuscular injection of saline alone or with CTX followed by
isolation of the TA muscle at different time points and processing for Hematoxylin and
Eosin (H&E) staining. Intramuscular injection of CTX caused equal necrosis in TA muscle
of both TRAF6f/f and TRAF6mko mice examined at 2d post CTX injection (data not shown).
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Interestingly, regeneration of TA muscle was dramatically improved in TRAF6mko mice
compared to TRAF6f/f littermates (Figure 2.2). TA muscle of TRAF6mko contained majority
of newly formed centronucleated fibers (CNF) and reduced cellular infiltrate at 5d post CTX
injection. Improved regeneration in TRAF6mko mice was also evident at 10d and 21d after
CTX injection (Figure 2.2). Morphometric analyses of CTX-injected TA muscle sections
showed about 36% improvement in average fiber cross-sectional area (CSA) in TRAF6mko
mice compared to TRAF6f/f littermates. Moreover, the number of fibers containing two or
more centrally located nuclei was significantly higher in TRAF6mko mice compared to
TRAF6f/f after 5d of CTX injection further suggesting accelerated regeneration of injured
myofibers in TRAF6mko mice (please refer to (84)).

2.3.2 Overexpression of TRAF6 worsens myofibers regeneration upon injury. We next
studied the effects of overexpression of TRAF6 protein on adult myofiber regeneration.
Left-side TA muscle of C57BL6 mice was electroporated with vector (pcDNA3) alone
whereas right-side with plasmid encoding wild-type TRAF6 cDNA. Protein levels of
TRAF6 were higher in TA muscle transfected with TRAF6 cDNA compared to that
transfected with pcDNA3 alone (Figure 2.1B). However, there was no overt phenotype in
TRAF6-transfected TA muscle compared to those transfected with vector alone in
unchallenged conditions, studied 7d post electroporation (Figure 2.1C). Next, TA muscle
was injected with CTX followed by analysis of muscle regeneration at 5d and 7d by H&E
staining. Interestingly, overexpressing of TRAF6 inhibited the regeneration of TA muscle
(Figure 2.3). The TRAF6 cDNA-transfected TA muscle contained considerably increased
amount of cellular infiltrate (darkly stained nuclei of inflammatory cells) both at 5d and 7d
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after CTX injection (Figure 2.3). In addition, the number of regenerating myofibers and the
fiber cross-sectional area were noticeably reduced in TRAF6-transfected myofibers (Figure
2.3). These results indicate that TRAF6 inhibits the regeneration of adult myofiber upon
injury.

2.3.3 Depletion of TRAF6 improves formation of new myofibers in response to injury.
A shift from degenerative to regenerative stage is followed by transition of myogenic cells
through expression of specific transcription factors and related genes. This pattern also
mimics the embryonic development of skeletal muscle (1). CTX injection in mouse skeletal
muscle stimulates the expression of MyoD in satellite cells by 2d. Thereafter, a decline in
MyoD expression and an increase in myogenin expression occur by 3d post-injury followed
by a consequential and persistent elevation of embryonic form of myosin heavy chain
(eMyHC) (85, 86). Furthermore, as a regenerating muscle progresses towards normal
architecture, embryonic isoform of MyHC is replaced by adult isoform. To investigate
whether depletion of TRAF6 causes any change in the temporal expression pattern of these
markers, we further examined CTX-injected TA muscle of TRAF6f/f and TRAF6mko mice.
Immunostaining revealed more uniform and abundant expression of eMyHC in TA muscle
of TRAF6mko compared to TRAF6f/f mice at 5d after CTX injection (Figure 2.4A). Western
blot analysis showed that TRAF6 levels were reduced in uninjured TA muscle of TRAF6mko
mice compared to TRAF6f/f mice. Furthermore, TRAF6 levels in CTX-injected TA muscle
of TRAF6mko mice was ~50% less compared to corresponding TRAF6f/f mice (Figure 2.4B)
suggesting that infiltrating cells and myofibers contribute almost equally to the increased
levels of TRAF6 in CTX-injected TA muscle.
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IGF-1 is a major growth factor which induces skeletal muscle regeneration through
augmenting the proliferation and differentiation of myogenic cells. We next investigated
whether signaling through TRAF6 also affects the expression of IGF-1 in injured skeletal
muscle. As shown in Figure 2.4C, transcript levels of IGF-1 were significantly higher in
CTX-injected TA muscle of TRAF6mko compared to TRAF6f/f mice (Figure 2.4C).
Moreover, increased mRNA levels of myogenin in CTX-injected TA muscle of TRAF6mko
mice affirmed enhanced muscle regeneration in these mice compared to TRAF6f/f mice at 6d
post CTX-mediated injury (Figure 2.4C). Collectively, these results suggest that depletion
of TRAF6 in adult myofibers accelerates muscle regenerative program upon injury.

2.3. 4 Inhibition of TRAF6 promotes satellite cells activation in injured myofibers in
vivo: Muscle injury is followed by the activation of satellite cells which is prerequisite for
induction of efficient regeneration program in injured muscle (1, 4). We next investigated
whether TRAF6-mediated signaling affects the activation of satellite cells in injured
myofibers. Pax7 is a marker of both quiescent and activated satellite cells (64, 87). We first
performed immunostaining for Pax7 to evaluate the number of satellite cells in TA muscle
of TRAF6f/f and TRAF6mko mice. There was no noticeable difference in the number of
Pax7+ cells between uninjured TA muscle of TRAF6f/f and TRAF6mko mice. However, the
number of Pax7+ cells per unit area was considerably higher in TA muscle of TRAF6mko
compared to TRAF6f/f mice at 5d post CTX injection (Figures 2.5A, 2.5B).
A unique combination of cell surface markers (CD45−, CD31−, Ter119−, Sca-1-, α7β1 integrin+) identify satellite cells in adult mouse skeletal muscle and allow their direct
quantification by fluorescence-activated cell sorting (FACS) technique (88). To further
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evaluate whether signaling through TRAF6 affects the activation of satellite cells in injured
muscles, we also performed FACS analysis. There was no difference in the number of
satellite cells in uninjured TA muscle of TRAF6f/f and TRAF6mko mice. However,
intramuscular injection of CTX significantly increased the number of satellite cells in TA
muscle of both TRAF6f/f and TRAF6mko mice measured at 5d (Figures 2.5C and 2.5D).
Furthermore, the number of satellite cells was significantly higher in CTX-injected TA
muscle of TRAF6mko mice compared to littermate TRAF6f/f (~7.5% in TRAF6f/f vs. ~13% in
TRAF6mko) mice (Figures 2.5C and 2.5D).

2.3.5 Ablation of TRAF6 promotes activation and self-renewal of satellite cells in single
myofiber cultures. Suspension culture of myofiber explants represents an ex-vivo model
that mimics muscle injury in vivo with respect to satellite cell activation, proliferation, and
differentiation (57, 64, 87). Upon isolation, each myofiber is associated with a fixed number
of (Pax7+/MyoD-) satellite cells resting in quiescence. At around 24h in culture, satellite cells
undergo their first round of cell division, through up regulating MyoD (Pax7+/MyoD+) and
proliferating to form cell aggregates. Cells then either terminally differentiate (Pax7+
/MyoD )

or self-renew (Pax7+/MyoD-) (64). Consistent with our in vivo results,

immunostaining of freshly isolated myofibers from EDL muscle of TRAF6mko and their
littermates TRAF6f/f revealed comparable numbers of (Pax7+ /MyoD-) cells and negligible
levels of MyoD expression (data not shown). After 72h in suspension culture, a dramatic
increase was observed in the number of Pax7+ /MyoD- as well as Pax7+/MyoD+ cells in
TRAF6mko compared to TRAF6f/f (Figures 2.6A-E) accompanied by an upregulation of cells
expressing the proliferation marker Ki67. Moreover, the number of cells per cellular
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aggregate was also increased, characterized by an upregulation of Pax7+ /MyoD- cells
(Figures 2.6D-I). Further analysis of clusters on myofibers in suspension cultures showed
that while there was a significant increase in proportion of Pax7+/MyoD- cells (Figure
2.6F), there was no significant difference in the distribution of Pax7+/MyoD+ cells (Figure
2.6G) in cellular aggregates of TRAF6f/f and TRAF6mko myofibers suggesting that while
ablation of TRAF6 increases the proliferation and self-renewal, it also favors restoration of
satellite cell pool by significant margin.

2.3.6 TRAF6 inhibits Notch signaling in regenerating myofibers. Notch signaling is an
important regulator of cell proliferation, cell fate determination, and in asymmetric cell
division during embryogenesis. Moreover, the role of Notch signaling in orchestrating
satellite cell activation in regenerative adult muscle is well documented (56). To determine
whether the accelerated regenerative phenomenon observed in TRAF6 ablated skeletal
muscle is brought about through a Notch-dependent manner, transcript levels of a set of
Notch target genes were analyzed using QRT-PCR technique. A significant increase in
mRNA level of Hes1, Hes6, Hey1, HeyL and Nrarp was observed in CTX-injected TA
muscle of TRAF6mko muscle compared to TRAF6f/f mice (Figure 2.7A). Additionally,
transcript levels of Notch3 receptor (Figure 2.7B) and Notch ligands DLL1, DLL2,
Jagged1, and Jagged2 (Figure 2.7C) were unregulated in CTX-injected TA muscle of
TRAF6mko mice compared to TRAF6f/f mice. Western blot analysis also showed that the
protein levels of Jagged2 were ~2.2 fold and DLL1 ~1.7 fold higher in regenerating TA
muscle of TRAF6mko mice compared to TRAF6f/f mice (Figure 2.7D). Notch signaling
involves the interaction between two neighbor cells, one expressing Notch ligand and other
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expressing Notch receptors (56, 57). Since in our model, we depleted TRAF6 specifically in
differentiated myofibers, by performing immunostaining, we tested the hypothesis that
inhibition of TRAF6 increases the expression of Notch ligands in regenerating myofibers.
As shown in Figure 5E, Jagged2 protein co-localized with eMyHC in CTX-injected TA
muscle of both TRAF6f/f and TRAF6mko mice. Furthermore, the expression of Jagged2 was
higher around injured/regenerating myofibers of TRAF6mko compared to TRAF6f/f mice
(Figure 2.7E). Similar, immunostaining analysis revealed that Jagged2 was expressed in
myofibers in suspension cultures and the level of expression was increased in cultured
myofibers from TRAF6mko mice compared to TRAF6f/f mice (Figure 2.7F).
We also studied the activation of Notch signaling pathway in satellite cells of
TRAF6f/f and TRAF6mko mice. TA muscle of TRAF6f/f and TRAF6mko mice were given
intramuscular injection of CTX for 5d and satellite cells were isolated using fluorescenceactivated cell sorting (FACS) method followed by QRT-PCR assay to study the expression
levels of Notch target genes. Interestingly, the mRNA levels of Hes6, HeyL, and Nrarp were
found to be significantly higher in satellite cells from TRAF6mko mice compared to TRAF6f/f
mice (Figure 2.7G) indicating higher activation of Notch signaling pathway in satellite cells
of injured myofibers of TRAF6mko mice.

2.3.7 Inhibition of Notch signaling blunts the proliferation and self-renewal of satellite
cells in myofiber cultures of TRAF6f/f and TRAF6mko mice. Although the role of Notch
signaling in satellite cell activation and self-renewal and muscle regeneration has been
established using both genetic mouse models and pharmacological inhibitors (3, 57, 64-69),
we further investigated whether the higher levels of activation of Notch pathway is
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responsible for the increased proliferation of satellite cells in myofibers of TRAF6mko mice.
Previous studies have shown that -secretase inhibitor DAPT (N-[2S-(3,5difluorophenyl)acetyl]-L-alanyl-2-phenyl-1,1-dimethylethyl ester-glycine) efficiently
inhibits the activation of Notch signaling in various cell types including satellite cells (64,
66). DAPT function by inhibiting the cleavage of Notch intracellular domain (NICD) from
transmembrane domain of Notch receptor and hence block the downstream Notch signaling.
Single myofibers were prepared from TA muscle of TRAF6f/f and TRAF6mko mice and
treated with DAPT followed by immunostaining for Pax7, MyoD, and/or Ki67. Nuclei were
identified by co-staining with DAPI. Consistent with published reports, DAPT reduced the
number of clusters, average number of satellite cells per cluster, and the number of Ki67+
cells in myofibers of both TRAF6f/f and TRAF6mko mice (Figure 2.8). Interestingly,
treatment with DAPT completely blunted the increased proliferative response of satellite
cells observed in cultured myofibers of TRAF6mko mice. Similarly, the proportion of
Pax7+/MyoD- and Pax7+/MyoD+ cells was also dramatically reduced upon treatment with
DAPT (Figure 2.8). Collectively, these results demonstrate that depletion of TRAF6 in
differentiated myofibers induces satellite cell proliferation and self-renewal through Notch
signaling pathway.

2.4 DISCUSSION
Skeletal muscle regeneration involves activation of a complex array of signaling proteins not
only in satellite cells and myoblasts but also in regenerating myofibers. However, except
NF-B where its targeted inhibition in adult/differentiated myofibers improved regeneration
(78), majority of the studies have been performed employing myoblast- or satellite cell-
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specific knockout mice or global knockout mouse models which made no distinction
between signals originating in muscle progenitor cells and injured myofibers. Moreover, the
initial events which govern the activation of downstream signaling pathways in regenerating
myofibers remain poorly understood. In the present study, we provide genetic evidence that
signaling through TRAF6 negatively regulate adult myofiber regeneration. We have also
uncovered a previously unrecognized link between TRAF6, Notch signaling, and skeletal
muscle regeneration. Our results demonstrate that the inhibition of TRAF6 up-regulates the
expression of Notch ligands leading to enhanced Notch driven activation of satellite cells.
Studies from our lab has also shown that blocking TRAF6 in differentiated myofibers
inhibits the activation of NF-B and increases levels of promyogenic M2c macrophages in
regenerating skeletal muscle potentially through a cross-talk with Notch pathway (84).
Following muscle injury, quiescent satellite cells present in basal lamina get
activated, which proliferate and finally fuse with injured myofibers leading to regeneration
and repair (1, 52). Notch signaling is critical not only for the activation of satellite cells but
also for their terminal differentiation into myofibers and to maintaining the satellite cell pool
(3, 57, 64-69). We found that the depletion of TRAF6 specifically in differentiated
myofibers significantly increases the number of satellite cells upon injury leading to rapid
and faster restoration of muscle architecture. Similarly, satellite cells associated with
cultured TRAF6mko myofibers displayed increased proliferative potential accompanied by
up-regulation of Pax7+/MyoD- and Pax7+/MyoD+ satellite cells (Figure 2.6). Transcriptional
analysis of injured myofibers from TRAF6mko compared to their TRAF6f/f littermates
denoted an augmentation of Notch signaling cascade evident by enhanced levels of Notch
ligands (DLL1, DLL2, Jagged1, and Jagged2), Notch3 receptor, and a subset of Notch
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target genes (Hes1,Hes6,Hey1,HeyL and Nrarp). This suggests that the inhibition of TRAF6
leads to the production of certain factors from regenerating myofibers and/or create a muscle
microenvironment which augments Notch signaling resulting in the activation of resident
satellite cells. Alternatively, the increased expression of Notch ligands on injured myofibers
itself could be sufficient to activate Notch signaling in satellite cells residing on these
myofibers. This later possibility is strongly supported by our results demonstrating that the
expression of Jagged2 was noticeably higher in the periphery of regenerating myofibers of
TRAF6mko mice (Figure 2.7). Furthermore, freshly isolated satellite cells from CTXinjected TA muscle of TRAF6mko mice showed increased mRNA levels of Notch target
genes suggesting increased Notch signaling in satellite cells (Figure 2.7). Although the
current study identifies TRAF6 signaling as being a negative regulator for the expression of
Notch ligands on injured myofibers, one can next enquire as to the mechanism by which
TRAF6 suppresses the expression of Notch ligands. This is an area of interest for future
investigation.
Several molecules such as IGF-1, fibroblast growth factor, and hepatocyte growth
factor have now been identified which affect the proliferation and/or differentiation of
muscle progenitor cells (1, 52). Among them, IGF-1 is a well-known growth factor which
stimulates both the proliferation and differentiation of muscle progenitor cells in vivo and in
vitro (89). It has also been reported that muscle-specific overexpression of IGF-1 augments
regeneration of myofibers in response to injury (90). Interestingly, the expression of IGF-1
was significantly higher in injured myofibers of TRAF6mko mice compared to TRAF6f/f
(Figure 2.4C) suggesting that the improved muscle regeneration in TRAF6mko mice could
also be a result of increased production of IGF-1.
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NF-B is one of the important signaling pathways activated through TRAF6dependent mechanisms in response to various cytokines, growth factors, and recruitment of
toll-like receptors (27, 91). NF-κB activation can occur via either the canonical or alternative
pathway (92). In absence of activating stimuli, NF-κB dimers are retained in the cytoplasm
by binding to specific inhibitors-the inhibitors of NF-κB (IκBs). The classical pathway is
IKKβ and IKKγ-dependent and NF-κB activation occurs through the degradation of IκB
proteins (77, 92). Activated IKK phosphorylates NF-κB-bound IκB proteins and targets
them for polyubiquitination and rapid degradation. Proinflammatory cytokines such as TNFα activate NF-κB through IKKβ-mediated site-specific phosphorylation and subsequent
ubiquitination and degradation of inhibitory protein IκBα by the 26S proteasome. NF-B
complexes liberated from IB inhibitory proteins then translocate to the nucleus leading to
transcriptional activation of several target genes (92). In addition to this classical activation
mechanism involving IκB degradation, post-translational modifications of p65 by
phosphorylation, acetylation, and ubiquitination have been shown to modulate the transactivation potential of NF-B (92). Inhibition of NF-B in differentiated muscle improves
their regeneration in response to CTX-mediated injury (78) and in the mdx model of
Duchenne muscular dystrophy (16). Coincidently, we found that the DNA binding activity
of NF-B and the transcript levels of TNF-α and IL-1β were reduced in injured skeletal
muscle of TRAF6mko mice (84). These results are also in agreement with our recently
published report demonstrating that TRAF6 mediates the activation of NF-B in skeletal
muscle in response to catabolic stimuli such as denervation and cancer cachexia (41).
Cross-talk between NF-B and Notch signaling pathways has been implicated in
different cellular contexts (79, 80). Cytoplasmic sequestration of p65 by IBα was shown to
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both translocate nuclear corepressors SMRT (silence mediator for retinoic acid and thyroid
receptors)/N-CoR (nuclear receptor corepressor) to the cytoplasm and upregulate
transcription of Notch-dependent genes (93). Moreover, p65 and IBα are able to directly
bind SMRT, and this interaction can be inhibited in a dose-dependent manner by the CREB
binding protein (CBP) coactivator and after TNFα treatment, suggesting that stimuli that
promote IBα degradation, p65 acetylation and NF-B activation, such as TNFα, inhibit
Notch-dependent transcriptional activity (93). More recently, it has been reported that TNFα
is capable of inhibiting Notch1 in satellite cells and C2C12 myoblasts through NF-Bdependent manner (94). Thus, the reduced expression of TNF-α and suppression of NF-B
activity may be another mechanisms for the increased Notch signaling in regenerating
myofibers of TRAF6mko mice.
While the role of TRAF6 in innate immune response has been extensively studied,
there is a dearth of information on its mediation in activation of different phenotypes of
macrophages. Accumulating evidence suggests that macrophage phenotype transition is
critical for the regeneration of skeletal muscle upon injury because proinflammatory (M1)
and anti-inflammatory (M2c) macrophages exert antagonistic effects on myogenesis (95).
Initial activation of proinflammatory macrophages is mediated by inflammatory cytokines
which is not influenced by muscle cells. However, as the regeneration progresses, cytokines
produced by muscle cells may also contribute towards prolonged activation of macrophages
(95). TNF-α and IL-1β are two inflammatory cytokines produced by both M1 macrophages
and skeletal muscle cells (95-97). Increased levels of these cytokines facilitate the activation
of M1 macrophages and inhibit transition from M1 to M2 phenotype. Our results
demonstrate that the expression of both IL-1β and TNFα are decreased in injured myofibers
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of TRAF6mko mice which may be responsible for the reduced activation of M1 macrophages
(84). In contrast, IL-4 and IL-10 are predominately anti-inflammatory cytokines which
promote M2c phenotype of macrophages and induces the proliferation of satellite cells (98100). While we did not find any major difference in mRNA levels of IL-10, the expression
of IL-4 was increased in injured myofibers of TRAF6mko compared to TRAF6f/f mice (84).
This suggests that the inhibition of TRAF6 limits the levels of inflammatory cytokines
which hastens the appearance of M2c macrophages resulting in increased proliferation of
myogenic cells and rapid restoration of myofibers architecture.
It is also of interest to note that some of the pathways purported to be involved in
skeletal muscle regeneration or synthesis of new myofibers were not affected by depletion of
TRAF6. Ablation of TRAF6 did not have any major effect on the phosphorylation of Akt
kinase and p38MAPK (84). While these data are in contrast to previous reports of TRAF6dependent activation of Akt (36) and p38MAPK (101), they highlight TRAF6-mediated
differential activation of downstream signaling pathways (102). This context-dependent role
of TRAF6 supports our inference that in injury-induced regeneration of skeletal muscle,
TRAF6 acts as a negative regulator of myogenesis.
While the TRAF6-mediated signaling in differentiated myofibers inhibits their
regeneration upon injury, it is noteworthy that the role of TRAF6 could be quite different in
muscle progenitor cells. A published report suggests that siRNA-mediated knockdown of
TRAF6 in cultured C2C12 myoblasts inhibits their proliferation as well as differentiation
into multinucleated myotubes (42). Using siRNA electroporation approach, Xiao et al (103)
have recently investigated the in vivo role of TRAF6 in skeletal muscle regeneration. In
contrast to our study, they reported that TRAF6 is essential for skeletal muscle regeneration
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because its depletion through siRNA-mediated technique inhibited regeneration of injured
myofibers (103). However, in their study, they performed electroporation of TRAF6 siRNA
in TA muscle one day post CTX injection and continually performed the same procedure
every day before studying muscle regeneration. This implies that they depleted TRAF6 in all
cell types including satellite cells and immune and other cell types which infiltrate
myofibers after injury (103). While the specific in vivo role of TRAF6 in satellite cell
proliferation and differentiation requires further investigation using genetic mouse models,
in the present study, we have shown that TRAF6 signaling that specifically originates in
differentiated myofibers attenuates muscle regeneration program in response to injury.
In summary, TRAF6-mediated regulation of muscle regeneration unveiled by this
study provides an unanticipated link Notch signaling and satellite cell activation and muscle
formation in an injured tissue microenvironment. Considering the importance and limited
availability of therapeutic interventions that can influence the balance between inflammation
and myogenesis in pathological conditions such as muscular dystrophy, we believe that
interventions targeting TRAF6-mediated signaling will enhance the ability to improve
pathological conditions in inflammatory muscle disorders.
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FIGURE 2.1

FIGURE 2.1. Levels of TRAF6 in satellite cells of TRAF6f/f and TRAF6mko mice and
effects of overexpression of TRAF6 in uninjured muscle of WT mice. (A).
Representative immunoblots presented here demonstrate protein levels of TRAF6 and
tubulin in cultured satellite cells of TRAF6f/f and TRAF6mko mice. (B) TA muscle of 10week old C57BL6 mice was electroporated with pcDNA3 alone or pcDNA3-TRAF6
plasmid. After 7 days, the TA muscle was isolated and analyzed. Immunoblot presented here
demonstrates increased levels of TRAF6 in pcDNA3-TRAF6 electroporated TA muscle.
The level of an unrelated protein tubulin was comparable between TA muscle electroporated
with pcDNA3 or pcDNA3-TRAF6 plasmids. (C). Representative photomicrographs of
H&E-stained transverse sections of TA muscle 7 days after electroporation with pcDNA3
or pcDNA3-TRAF6 plasmids. Scale bar: 20µm.
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FIGURE 2.2

FIGURE 2.2. Ablation of TRAF6 improves skeletal muscle regeneration in mice. TA
muscle of 8-week old WT mice was injected 100µl of saline alone or containing 10 µM
cardiotoxin (CTX) and analyzed at 5d. Representative immunoblots of TRAF6 and an
unrelated protein tubulin in saline and CTX-injected tibial anterior (TA) muscle. N=3 at
each time point. Scale bar: 20 µm.
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FIGURE 2.3

pcDNA3-TRAF6

7 days

5 days

pcDNA3

FIGURE 2.3 Overexpression of TRAF6 reduces myofibers regeneration upon injury.
TA muscle of WT mice was electroporated with pcDNA3 or pcDNA3-TRAF6 plasmids.
After 7d, the muscle was injected with 100 µl of 10 µM CTX solution followed by their
isolation and performing H&E staining. Representative photomicrographs of H&E-stained
transverse sections at 5d and 7d post CTX injection are presented here. N=3 at each time
point. Scale bar: 20 µm.
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FIGURE 2.4

FIGURE 2.4 Ablation of TRAF6 accelerates restoration of muscle architecture after
injury. TRAF6f/f and TRAF6mko mice were injected with saline or CTX in TA muscle
followed by their isolation and analyses at 5d. . (A) Transverse sections of CTX-injured TA
muscle from TRAF6f/f and TRAF6mko mice stained with anti-eMyHC (embryonic myosin
heavy chain) or isotype control (mouse IgG). (B) Western blot analysis of expression levels
of TRAF6, and tubulin in saline or CTX-injected TA muscle from TRAF6f/f and TRAF6mko
mice. (C) Transcript levels of IGF-1 and myogenin in TA muscle of TRAF6f/f and
TRAF6mko mice measured at 5d post CTX injection. Error bars represent SD. N=4 in each
time point. *p < 0.01, values significantly different from CTX-injected TA muscle of
TRAF6f/f mice.
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FIGURE 2.5
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FIGURE 2.5. Ablation of TRAF6 promotes the activation of satellite cells during
muscle regeneration. Three months old TRAF6f/f and TRAF6mko were injected with saline
or CTX in TA muscle and analyzed after five days. (A) Representative photomicrographs
after immunostaining of transverse muscle sections with Pax7 antibody. Nuclei were
identified by co-staining with DAPI. Arrows points to Pax7+ cells. (B) Average number of
Pax7+ cells per field (∼0.15 mm2) in saline and 5d CTX-injected TA muscle of TRAF6f/f and
TRAF6mko mice. (C) FACS analysis of saline or CTX-injected TA muscle for α7β1-integrinpositive activated satellite cells in TRAF6f/f and TRAF6mko mice. Representative dot plots
are shown. Negative selection antibodies (CD45, CD31, Ter119, Sca-1) are gated in red
whereas positive selection antibody (α7β1-Integrin) is gated in blue. (D) Quantification of
activated satellite cells in saline or CTX-injected TA muscles of TRAF6f/f and TRAF6mko
mice by FACS. Error bars represent SD. N=6 in each group. *p < 0.01, values significantly
different from contralateral saline-injected TA muscle; #p < 0.01, values significantly
different from CTX-injected TA muscle of TRAF6f/f mice.
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FIGURE 2.6
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FIGURE 2.6. Ablation of TRAF6 promotes proliferation and self-renewal of satellite
cells. Single myofiber cultures were established from EDL muscle of TRAF6f/f and
TRAF6mko mice. (A) After 72h, myoblast clusters on the single myofibers were labeled with
antibodies against Pax7 and MyoD. Nuclei were counterstained with DAPI. Representative
merged images of Pax7, MyoD, and DAPI staining are presented here. (B) Average number
of clusters (containing >4 cells per fiber) per myofiber of TRAF6f/f and TRAF6mko
calculated from 35 myofibers in each group. (C) Number of myoblasts per cluster in
TRAF6f/f and TRAF6mko mice (n=22). (D) In a separate experiment, myoblasts were also
stained with proliferation marker Ki67 and DAPI and the number of Ki67+ cells per cluster
were enumerated. (E and F) Percentage of self-renewing (Pax7+MyoD-) and proliferating
(Pax7+/MyoD-) myoblasts in TRAF6f/f and TRAF6mko myoblast colonies (calculated from 22
cultured colonies in each group). *p < 0.01, values significantly different from CTX-injected
TA muscle of TRAF6f/f mice.
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FIGURE 2.7
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FIGURE 2.7. Muscle-specific inhibition of TARF6 activates Notch signaling upon
injury. TA muscle of TRAF6f/f and TRAF6mko mice were injected with cardiotoxin (CTX)
and 5d later the muscle were isolated and processed for QRT-PCR, Western blot, or
immunostaining. Relative mRNA levels of (A) Notch target genes Hes1, Hes6, Hey1, HeyL,
and Nrarp; (B) Notch receptors Notch1, Notch2, and Notch3; and (C) Notch ligands
Jagged1, Jagged2, DLL1, and DLL2 in CTX-injected TA muscle of TRAF6f/f and
TRAF6mko mice. N=6 in each group. (D) Western blot analysis of Jagged2 and DLL1
protein in saline or CTX-injected TA muscle of TRAF6f/f and TRAF6mko mice. (E) CTXinjected TA muscle transverse frozen sections were stained for embryonic myosin heavy
chain (eMyHC) and Jagged2. Representative photomicrographs presented here demonstrate
increased immunostaining for Jagged2 in myofibers of TRAF6mko mice compared to
TRAF6f/f mice. (F) Single myofiber cultures were prepared from TRAF6f/f and TRAF6mko
mice. After 24h in cultures, myofibers (n=12) were stained for Jagged2. (G) Relative mRNA
levels of Notch-target genes Hes6, HeyL, and Nrarp in satellite cells isolated by FACS
method from 5d CTX-injected TA muscle of TRAF6f/f (N=3) and TRAF6mko (N=3) mice.
Bars represent SD. *p<0.05, values significantly different from corresponding TRAF6f/f
mice.
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FIGURE 2.8

44

FIGURE 2.8. Activation of Notch pathway causes activation and self-renewal of
satellite cells on cultured myofibers of TRAF6mko mice. Single myofiber cultures were
established from EDL muscle of TRAF6f/f and TRAF6mko mice. After 48h, myofibers were
treated with vehicle alone or along with 10µm for DAPT. Myoblasts on single myofibers
were stained with antibodies against Pax7, MyoD, and/or Ki67 and nuclei were counter
stained with DAPI. (A) Average number of clusters (containing >4 cells per fiber) per
myofiber of DAPT-treated TRAF6f/f and TRAF6mko myofiber cultures (calculated from 18
myofibers in each group). (B) Number of myoblasts per cluster in DAPT-treated myofiber
cultures from TRAF6f/f and TRAF6mko mice (n=16). (C) Number of Ki67+ cells per cluster.
(D and E) Percentage of self-renewing (Pax7+MyoD-) and proliferating (Pax7+/MyoD+)
myoblasts in TRAF6f/f and TRAF6mko myoblast colonies (calculated from 17 cultured
colonies in each group). Bars represent SD. *p<0.05, values significantly different from
corresponding TA muscle of TRAF6f/f mice.
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CHAPTER 3
DISTINCT ROLES OF TRAF6 AT EARLY AND LATE STAGES OF
MUSCLE PATHOLOGY IN THE MDX MODEL OF DUCHENNE
MUSCULAR DYSTROPHY

3.1 INTRODUCTION
Duchenne muscular dystrophy (DMD) is a devastating and ultimately fatal disease
characterized by progressive muscle wasting and weakness. The absence of dystrophin is a
key factor in developing DMD (104). Dystrophin is a critical component of dystrophinglycoprotein complex (DGC), which links the cytoskeleton to the extracellular matrix thus
maintaining muscle fiber membrane integrity. (8). Although the primary genetic defect is
known, the dystrophic process has not been clearly identified (10, 11). Studies in animal
models and humans have shown that the primary deficiency of dystrophin results in the
activation of several pathological cascades such as extracellular matrix breakdown,
oxidative stress, cycles of fiber degeneration and regeneration, inflammatory response, and
gradual replacement of muscle fibers with adipose and connective tissue (10, 12-15).
Besides acting as a molecular scaffold serving mechanical function, accumulating evidence
suggests that DGC also has an important signaling role in striated muscle. Loss of
dystrophin in skeletal muscle leads to aberrant activation of a number of signaling pathways
such as nuclear factor-B (NF-B), phosphatidylinositol 3-kinase (PI3K)/Akt, and mitogenactivated protein kinases (16-21). Interestingly, many of these signaling pathways are
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activated even at pre-necrotic state and their modulation using molecular and
pharmacological approaches considerably improves muscle pathology in models of DMD
(16-18, 20, 21). However, given the progressive degenerative nature of DMD and the
convoluted involvement of many secondary processes, developing a pan therapeutic strategy
that proves beneficial during the course of the disease has been challenging. Despite the
identification of many of the principal and auxiliary signaling pathways that contribute to
myopathy, the proximal signaling events leading to the activation of such pathological
cascades in dystrophic muscle remain unknown.
TNF receptor-associated factors (TRAFs) are a family of conserved adaptor proteins
which act as signaling intermediates for several receptor-mediated signaling events leading
to the context-dependent activation of a number of signaling pathways (48, 49). TRAF6
functions as a signal transducer to activate IB kinase (IKK) and subsequently NF-B
activation in response to proinflammatory cytokines, bacterial products, Toll/IL-1 family
and from receptors such as receptor activator of NF-κB (RANK) and CD40 (25, 27, 37, 49).
TRAF6 is also an E3 ubiquitin ligase which undergoes autoubiquitination and catalyzes K63
polyubiquitination of TAK1 that is required for IKK activation (29, 105). TRAF6 interacts
with ubiquitin conjugating enzymes UBE2N/UBC13 and UBE2V1/UEV1A to stimulate the
formation of polyubiquitin chains on IKK. This protein also causes the K63-linked polyubiquitination of Akt which leads to its translocation to cell membrane, phosphorylation,
and enzymatic activation (36). Other signaling proteins such as interleukin-1 receptorassociated kinase 1 (IRAK1), Src family kinase, and protein kinase C zeta (PKC) have also
been found to interact with TRAF6 further signifying a central role of TRAF6 in cross-talk
between different signaling pathways (27, 37, 49). Moreover, TRAF6 interacts with scaffold

47

protein p62/Sequestosome 1 which is involved in regulation of autophagy and TRAFficking
of proteins to the proteasome (37-40). It has been also found that TRAF6 promotes the K63linked ubiquitination of Beclin-1, which is critical for the induction of autophagy, in
response to toll-like receptor 4 signaling (46). However, the role of TRAF6 signaling in
muscular dystrophy remains unknown.
Accumulating evidence suggests that TRAF6 is a crucial regulator of skeletal muscle
mass in catabolic states (41, 43, 84). Abundance and activation of TRAF6 are increased in
skeletal muscle of mice in many atrophying conditions. Notably, inhibition of TRAF6 using
genetic approaches attenuates muscle-wasting in response to denervation, cancer cachexia,
and starvation (41, 43). Furthermore, specific inhibition of TRAF6 also improves myofiber
regeneration upon cardiotoxin-mediated injury (84). One of the mechanisms by which
TRAF6 mediates muscle-wasting is through stimulation of autophagy (41, 43). Autophagy is
an important homeostasis mechanism which is essential for clearing of dysfunctional
organelles and preventing tissue damage (106). While basal level of autophagy is required
for the maintenance of skeletal muscle mass, excessive autophagosome formation generally
leads to muscle-wasting (106-110). Interestingly, autophagy has been found to be impaired
in muscle biopsies from patients with DMD and in skeletal muscle of mdx mice with
concomitant accumulation of damaged organelles (111). However, the role of TRAF6 in
regulation of autophagy in the “settings” of muscular dystrophy remains unknown.
In this study, we have investigated the role and the mechanisms by which TRAF6
affects disease progression in mdx (a mouse model of DMD) mice. Our results show that
depletion of TRAF6 attenuates injury and inflammation and improves muscle structure and
regeneration in young mdx mice. By contrast, continued inhibition of TRAF6 causes fiber
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degeneration and fibrosis at later stages of mdx mouse development potentially through
inhibition of autophagy.

3.2 MATERIALS AND METHODS
Mice. Wild-type (strain: C57BL/10 ScSn) and mdx (strain: C57BL/10 ScSn DMDmdx) mice
were purchased from Jackson Laboratory (Bar Harbor, ME, USA). Floxed TRAF6
(TRAF6f/f) and muscle-specific TRAF6-knockout (TRAF6mko) mice have been previously
described (41, 43). TRAF6mko mice were crossed with mdx mice for 5-6 generations to
generate littermate mdx;TRAF6f/f and mdx;TRAF6mko mice. All genotypes were determined
by PCR analysis from tail DNA. Mice were housed in the animal facility of the University
of Louisville under conventional conditions with constant temperature and humidity and fed
a standard diet. All experiments with animals were approved by the Institutional Animal
Care and Use Committee of the University of Louisville.

Creatine kinase (CK) assay: The serum level of CK was determined using a commercially
available kit (Stanbio Laboratory, TX).

Histology and morphometric analysis. Skeletal muscle tissues were isolated, frozen in
isopentane cooled in liquid nitrogen, and sectioned in a microtome cryostat. For the
assessment of tissue morphology, 10-µm-thick transverse sections of each muscle were
stained with Hematoxylin and Eosin (H&E), and staining was visualized on a microscope
(Eclipse TE 2000-U), a digital camera (Digital Sight DS-Fi1), and NIS Elements BR 3.00
software (all from Nikon). The images were stored as JPEG files, and image levels were
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equally adjusted using Photoshop CS2 software (Adobe). Pictures of the whole muscle
sections were captured and the percentage of centrally nucleated fibers was counted in the
entire muscle section. To quantify the variation in fiber size, fiber cross-sectional area was
measured for every fiber in each section using Nikon NIS Elements BR 3.00 software
(Nikon). Variability in cross-sectional areas between samples was expressed as the mean of
the standard deviations for each population. Necrotic area in H&E-stained sections was
determined by measuring percentage area filled with cellular infiltrate in whole muscle
section. Mean minimum feret diameter of eMyHC+ fibers was determined after measuring
cross sectional area for each fiber. The extent of fibrosis in muscle cryosections was
determined using a Trichrome staining kit following a protocol suggested by manufacturer
(American Master Tech).
For Immunohistochemical detection of macrophages, rat anti-mouse F4/80 (Serotec)
was used at at 1:500 dilution and horseradish peroxidase-labeled streptavidin biotin
technique (DAKO K5001 with E468) was used as a detection system. The concentrations of
F4/80+ cells were expressed as the number of cells per volume of each section.

Indirect Immunofluorescence. For immunohistochemistry study, muscle sections were
blocked in 1% bovine serum albumin in PBS for 1h, and incubated with anti-Pax7 (1:20,
Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA) or anti-EMyHC (1:150, Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA)
in blocking solution at 4C overnight under humidified conditions. The sections were
washed briefly with PBS before incubation with Alexa Fluor® 488 or 594-conjugated
secondary antibody (1:3000, Invitrogen) for 1h at room temperature and then washed 3
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times for 5 minutes with PBS. The slides were mounted using fluorescence medium (Vector
Laboratories) and visualized at room temperature on Nikon Eclipse TE 2000-U microscope
(Nikon), a digital camera (Nikon Digital Sight DS-Fi1), and Nikon NIS Elements BR 3.00
software (Nikon). Image levels were equally adjusted using Abode Photoshop CS2 software
(Adobe). Damaged/ permeabilized fibers in muscle cryosections were identified by
immunostaining with Cy3-labelled goat anti-mouse IgG (1:3000, Invitrogen).

Immunoprecipitation and Western blotting. Quantitative estimation of specific protein
was done by Western blot using a method as previously described (112). Briefly, individual
tissues were washed with phosphate-buffered saline (PBS) and homogenized in lysis buffer
A [50 mM Tris-Cl (pH 8.0), 200 mM NaCl, 50 mM NaF, 1 mM dithiotheritol (DTT), 1 mM
sodium orthovanadate, 0.3% IGEPAL, and protease inhibitors]. Approximately, 100µg
protein was resolved on each lane on 10% SDS-PAGE, electrotransferred onto nitrocellulose
membrane and probed using anti-TRAF6 (1:500 MBL International ), anti-TRAF2 (1:500;
Santa Cruz Biotechnology, Inc.), anti-TRAF3 (1:500; Santa Cruz Biotechnology, Inc ), antiLC3B (1:500; Cell signaling Technology), anti-Beclin (1:500; Cell signaling Technology),
anti-p62 (1:500; MBL International), anti-phospho-Akt (1:500; Cell Signaling Technology),
anti-Akt (1:500; Cell Signaling Technology), anti-phospho-mTOR (1:500; Cell Signaling
Technology), anti-mTOR (1:500; Cell Signaling Technology), anti-phospho-p70-S6K
(1:500; Cell Signaling Technology), anti-p70-S6K (1:500; Cell Signaling Technology), antiGADPH (1:2000; Cell Signaling Technology) and anti-tubulin (1:2000, Cell Signaling Inc)
and detected by chemiluminescence. To study the ubiquitination of TRAF6, muscle extract
(400 μg protein) was incubated overnight with 1 μg of anti-Ubiquatin antibody (Santa cruz
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Biotechnology, Inc.) in 600 μl of lysis buffer, protein A-Sepharose beads were added, and
the mixture was incubated at 4°C for an additional 2 h. The beads were washed four times
with lysis buffer and finally suspended in 2× Laemmli sample buffer. Proteins were resolved
on 10% SDS-PAGE gel and immunoblotted using TRAF6 antibody (1:500; MBL
International).

Electrophoretic Mobility Shift Assay (EMSA). The DNA binding activity of NF-B
transcription factor was measured using EMSA as detailed (21). Briefly, 20 µg of nuclear
extract prepared from skeletal muscle was incubated with 16 fmol 32P- ATP-end-labeled
NF-B consensus double-stranded oligonucleotide (Promega, MA) for 20 min at 37°C. The
incubation mixture included 2–3 µg of poly dI.dC in a binding buffer (25 mM HEPES [pH
7.9], 0.5 mM EDTA, 0.5 mM dithiothreitol, 1% IGEPAL, 5% glycerol, 50 mM NaCl). The
DNA-protein complex thus formed was separated from free oligonucleotides on a 7.5%
native polyacrylamide gel. The gel was dried, and radioactive bands were visualized and
quantitated by PhosphorImager using ImageQuant TL software (GE Healthcare, Piscataway,
NJ).
Quantitative real-time PCR (QRT-PCR): Real-time PCR for individual genes was
performed using an ABI Prism 7300 Sequence Detection System (Applied Biosystems)
using a method as previously described (112, 113). Briefly, the first strand cDNA reaction
(0.5 μl) from gastrocnemius muscle of individual control or mdx mice (n=4 in each group)
was subjected to real-time PCR amplification using gene-specific primers. The primers were
designed according to ABI primer express instructions using Vector NTI software and were
purchased from Sigma-Genosys (Spring, TX). The sequences of the primers used are as
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follows: TNF-α, 5’-GCA TGA TCC GCG ACG TGGAA-3’ (forward) and 5’AGATCCATGCCGTTGGCC AG-3’(reverse); IL-1β, 5’CTCCATGAGCTTTGTACAAGG-3’ (forward) and 5’-TGCTGATGTACCAGTTGGGG3’ (reverse); IL-6, 5’-CCTTCTTGGGACTGATGCTGG-3’ (forward) and 5’GCCTCCGACTTGTGAAGTGGT-3’ (reverse); MMP-9, 5’GCGTGTCTGGAGATTCGACTT G-3’ (forward) and 5’CATGGTCCACCTTGTTCACCTC-3’ (reverse); LC3B, 5′CTGGTGAATGGGCACAGCATG-3′ (forward) and 5’-CGTCCGCTGGTAACATCCCTT3’ (reverse); Beclin1, 5’-TGAAATCAATGCTGCCTGGG-3’ (forward) and 5’CCAGAACAGTATAACGGCAACTCC-3’ (reverse); p62, 5’AGCACAGGCACAGAAGACAAGAGT-3’ (forward) and 5’AATGTGTCCAGTCATCGTCTCCTC-3’ (reverse); Atrogin-1, 5’GTCGCAGCCAAGAAGAGAAAGA-3’ (forward) and 5’TGCTATCAGCTCCAACAGCCTT-3’ (reverse); MuRF1, 5’TAACTGCATCTCCATGCTGGTG-3’ (forward) and 5’TGGCGTAGAGGGTGTCAAACTT-3’ (reverse); and beta-actin, 5’ CAGGCATTGCTGACAGGATG-3’ (forward) and 5’-TGCTGATCCACATCTGCTGG-3’
(reverse).
Approximately 25 μl of reaction volume was used for the real-time PCR assays
which consisted of 2× (12.5 μl) Brilliant SYBR Green QPCR Master Mix (Stratagene), 400
nm of primers (0.5 μl each from the stock), 11 μl of water, and 0.5 μl of template. The
thermal conditions consisted of an initial denaturation at 95 °C for 10 min followed by 40
cycles of denaturation at 95 °C for 15 s, annealing and extension at 60 °C for 1 min, and, for
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a final step, a melting curve of 95 °C for 15 s, 60 °C for 15 s, and 95 °C for 15 s. All
reactions were carried out in triplicate to reduce variation. The data were analyzed using
SDS software version 2.0, and the results were exported to Microsoft Excel for further
analysis. Data normalization was accomplished using two endogenous control (-actin) and
the normalized values were subjected to a 2-ΔΔCt formula to calculate the fold change
between the control and experimental groups. The formula and its derivations were obtained
from the ABI Prism 7900 Sequence Detection System user guide.

Grip strength and wire hanging measurements. A digital grip-strength meter (Columbus
Instruments, Columbus, OH) was used to measure forelimb or total four-limb grip strength
in mice. Mice were acclimatized for 5 minutes before starting test. The mouse was allowed
to grab the metal pull bar with the forepaws and in a separate experiment with all four-paws.
The mouse tail was then gently pulled backward in the horizontal plane until it could no
long grasp the bar. The force at the time of release was recorded as the peak tension. Each
mouse was tested 5 times with a 20–40 seconds break between tests. The average peak
tension from three best attempts normalized against total body weight was defined as
forelimb grip strength. For wire hanging time evaluation, mice were placed on a grid in a
starting upright position. The grid was then gradually inverted above a cage filled with
bedding. Hanging time was determined as the longest time sustained hanging against gravity
from three repetitions.

Statistical analysis. Results are expressed as mean ± standard deviation (SD). Statistical
analysis used Student's t-test (two tailed) to compare quantitative data populations with
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normal distribution and equal variance. A value of P < 0.05 was considered statistically
significant unless otherwise specified.

3.3 RESULTS
3.3.1 TRAF6 levels are increased in skeletal muscle of mdx mice. In mdx mice, muscle
injury starts at around 2.5 weeks followed by peak necrotic phase in combination with
inflammation between 3-4 weeks of age (114, 115). Regeneration starts around the age of 6
weeks and continues while alternating with ongoing degeneration until 12 weeks of age
(116, 117). We first compared levels of TRAF6 in skeletal muscle of wild-type (WT) and
mdx mice at both pre-necrotic and necrotic stages. Diaphragm and gastrocnemius (GA)
muscle from 10, 14, 23, and 48 days old WT (i.e. C57BL10) and mdx mice were isolated
and processed to measure protein levels of TRAF6 by performing Western blot. Consistent
with our previously published results (41), the levels of TRAF6 were considerably higher in
young mice and reduced at later stages of development. However, levels of TRAF6 protein
were markedly higher in both diaphragm and GA muscle of mdx mice compared with WT
mice at all the ages (Figures 3.1A, 3.1B). In a separate experiment, we measured protein
levels of TRAF6 in quadriceps muscle of young (6-week) and old (9-month) WT and mdx
mice. The levels of TRAF6 were significantly higher in quadriceps muscle of both 6-week
and 9-month old mdx mice compared with their corresponding age-matched WT mice
(Figure 3.2). Increased levels of TRAF6 at 10 and 14 days in mdx mice also suggests that
levels of TRAF6 start increasing before the onset of fiber necrosis in mdx mice.
Since TRAF6 is an important E3 ubiquitin ligase which also undergoes
autoubiquitination to induce cellular signaling (33, 34, 43), we next investigated the levels
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of ubiquitinated TRAF6 protein in skeletal muscle of WT and mdx mice. Diaphragm was
isolated from 10, 14, 21, 23, and 48 days old mice and muscle extracts prepared were
immunoprecipitated using anti-ubiquitin followed by Western blot with anti-TRAF6.
Results showed that the levels of ubiquitinated TRAF6 protein were significantly higher in
mdx mice compared with WT mice at all the ages (Figure 3.1C). Together these data are
suggestive that the levels and activation of TRAF6 are increased in skeletal muscle of mdx
mice.

3.3.2 Targeted deletion of TRAF6 improves muscle strength in 7-week old mdx mice.
We have previously generated and characterized muscle-specific TRAF6-knockout mice
(TRAF6mko) by crossing floxed TRAF6 (TRAF6f/f) mice with muscle creatine kinase
(MCK)-Cre mice (41). MCK deletes floxed TRAF6 allele only in differentiated myofibers
but not in other cell type such as satellite cells, endothelial cells, and fibroblasts (41, 84). For
this study, we crossed TRAF6mko mice with mdx mice to obtain littermate mdx;TRAF6f/f
and mdx;TRAF6mko mice. We first measured the levels of TRAF6 in skeletal muscle of
mdx;TRAF6f/f and mdx;TRAF6mko mice at the age of 2-week (before the onset of fiber
necrosis). Levels of TRAF6 were found to be significantly reduced (~80%) in diaphragm
and gastrocnemius (GA) muscle of mdx;TRAF6mko mice compared with mdx;TRAF6f/f mice
(Figures 3.3A, 3.3B). The depletion of TRAF6 in mdx;TRAF6mko mice was specific
because levels TRAF2 and TRAF3 were comparable between mdx;TRAF6f/f and
mdx;TRAF6mko mice (Figure 3.3A). We next investigated whether depletion of TRAF6 in
skeletal muscle of mdx mice produces any developmental phenotype at prenecrotic state.
Hematoxylin and Eosin (H&E) staining of gastrocnemius (GA) muscle (Figure 3.3C) and
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diaphragm (data not shown) showed that depletion of TRAF6 does not produce any overt
phenotype in mdx mice at prenecrotic state.
We next performed systematic evaluation of muscle function in mdx;TRAF6f/f and
mdx;TRAF6mko mice. We first sought to investigate whether depletion of TRAF6 affects
muscle grip strength in mdx mice. Results showed that fore limb (Figure 3.3D) and total
four limb (Figure 3.3E) grip strength was significantly higher in mdx;TRAF6mko mice
compared to mdx;TRAF6f/f littermates at the age of 7-week. Furthermore, mdx;TRAF6mko
mice performed significantly better compared to mdx;TRAF6f/f mice on a wire hanging test
(Figure 3.3F) providing initial evidence that inhibition of TRAF6 signaling improves
muscle function in young mdx mice.

3.3.3 Depletion of TRAF6 improves muscle histopathology in young mdx mice.
Diaphragm, GA, quadriceps muscles of 7-week old mdx;TRAF6f/f and mdx;TRAF6mko mice
were isolated and processed for H&E staining. We observed typical features of dystrophic
muscle including variability in fiber cross-section area, central nucleation, fiber necrosis,
and cellular infiltrates within muscle cross-sections in skeletal muscle of mdx;TRAF6f/f
mice. However, these dystrophic features were considerably reduced in skeletal muscles of
mdx;TRAF6mko mice compared with mdx;TRAF6f/f mice (Figure 3.4A). Morphometric
analysis of H&E-stained muscle section showed that the necrotic area (i.e. that contains only
cellular infiltrate and no myofibers) was significantly reduced in skeletal muscle of
mdx;TRAF6mko mice compared with mdx;TRAF6f/f mice (Figure 3.4B). Furthermore,
proportion of centronucleated myofibers was also significantly reduced in skeletal muscle of
mdx;TRAF6mko mice compared with mdx;TRAF6f/f littermates (Figure 3.4C). Since serum
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creatine kinase (CK) level is an important marker of muscle injury, we also measured the
levels of CK in plasma. Our results showed that serum CK levels were significantly lower in
mdx;TRAF6mko mice compared with littermate mdx;TRAF6f/f mice (Figure 3.4D). By
performing immunostaining with Cy3-labeled anti-mouse IgG on muscle sections, we
further evaluated sarcolemmal injury in mdx;TRAF6f/f and mdx;TRAF6mko mice. Consistent
with serum CK activity, the number of IgG-filled fibers was significantly reduced in skeletal
muscle of mdx;Traf6mko mice compared with mdx;Traf6f/f mice (Figure 3.5). Taken
together, these data are suggestive that the depletion of TRAF6 inhibits muscle injury in
young mdx mice.

3.3.4 Inhibition of TRAF6 reduces macrophage accumulation, NF-B activation, and
expression of inflammatory cytokines in dystrophic muscle of young mdx mice.
Inflammation is a major pathological feature that contributes significantly to disease
progression in DMD (10, 118-120). To understand whether TRAF6 plays a role in
exacerbating inflammatory response in skeletal muscle of mdx mice, by performing
immunohistochemistry with F4/80 (a marker for macrophages) antibody, we studied the
accumulation of macrophages in diaphragm of 7-8 weeks old mdx;TRAF6f/f and
mdx;TRAF6mko mice. Interestingly, concentration of F4/80+ macrophages was found to be
significantly reduced in diaphragm of mdx;TRAF6mko mice compared with mdx;TRAF6f/f
mice (Figures 3.6A, 3.6B). NF-B is a major proinflammatory transcription factor that
leads to the expression of a wide variety of inflammatory cytokines, chemokines, and matrix
degrading enzymes (77, 121). To understand the mechanisms by which deletion of TRAF6
improves muscle inflammation in mdx mice, we studied the activation of NF-B by
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performing electrophoretic mobility shift assay (EMSA). DNA-binding activity of NF-B
was considerably reduced in both diaphragm and quadriceps muscle of mdx;TRAF6mko mice
compared with mdx;TRAF6f/f littermates (Figures 3.6C, 3.6D). Furthermore, transcript
levels of proinflammatory cytokines TNF-α, IL-1β, and IL-6, and a matrix degrading
enzyme, matrix metalloproteinase-9 (MMP-9) were significantly reduced in diaphragm of
mdx;TRAF6mko mice compared with mdx;TRAF6f/f mice (Figure 3.6E). These data
demonstrate that TRAF6 mediates NF-B activation and inflammatory response in myofiber
of mdx mice.

3.3.5 Depletion of TRAF6 improves myofiber regeneration in 7-week old mdx mice.
Accumulating evidence suggests that NF-B and inflammatory cytokines inhibit skeletal
muscle regeneration in mdx mice (16, 122, 123). We have also recently reported that
inhibition of TRAF6 improves myofiber regeneration upon cardiotoxin-mediated injury
(84). We next sought to investigate whether the inhibition of TRAF6 improves muscle
regeneration in mdx mice. We performed immunostaining on quadriceps muscle section
with an antibody that recognizes embryonic (developmental) myosin heavy chain (eMyHC).
Our analysis showed that eMyHC-positive fibers were generally scattered and smaller in
size in skeletal muscle mdx;TRAF6f/f mice. By contrast, the eMyHC-positive fibers were
more tightly packed in mdx;TRAF6mko compared to mdx;TRAF6f/f mice (Figure 3.7A, top).
Furthermore, the mean minimum Feret (MinFeret) diameter of eMyHC-positive fibers was
significantly higher in mdx;TRAF6mko mice compared with TRAF6f/f mice (Figure 3.7B).
Since satellite cells are mainly responsible for repair of injured myofibers in adults, we also
investigated whether depletion of TRAF6 in skeletal muscle of mdx mice affects the number
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of satellite cells. Quadriceps muscle sections from 7-week old mdx;TRAF6f/f and
mdx;TRAF6mko mice were stained for Pax7, a marker for quiescent and proliferating
satellite cells (2, 64, 82), and nuclei were counterstained with DAPI (Figure 3.7A, bottom).
Results showed that the number of satellite cells was significantly increased in quadriceps of
mdx;TRAF6mko mice compared with mdx;TRAF6f/f mice (Figure 3.7C). These results
suggest that the inhibition of TRAF6 improves satellite cells proliferation and myofiber
regeneration in mdx mice.

3.3.6 Inhibition of TRAF6 exaggerates myopathy in 9-month old mdx mice. Upon
confirming that the inhibition of TRAF6 improves muscle histopathology and regeneration
in 7-week old mdx mice, we next sought to determine whether the inhibition of TRAF6 will
also be effective in alleviating muscle pathology in older mdx mice. We first performed
histological analysis of skeletal muscle at the age of 5 months. Intriguingly, we did not find
any noticeable difference in muscle histopathology or level of fibrosis in skeletal muscle of
5-month old mdx;TRAF6f/f and mdx;TRAF6mko mice (data not shown). We next analyzed
skeletal muscle of these mice at the age of 9 months. Surprisingly, 9-month old
mdx;TRAF6mko mice showed increased muscle histopathology compared with
mdx;TRAF6f/f mice (Figure 3.8A). Skeletal muscle of TRAF6mko mice showed increased
necrotic area, cellular infiltrate, and variability in fiber size (Figures 3.8A-C). To detected
injured/permeable fibers in mdx mice, we also performed immunostaining with Cy3-labeled
anti-mouse IgG on GA muscle sections (Figure 3.8D). The number of IgG-filled fibers was
significantly higher in mdx;TRAF6mko mice compared with mdx;TRAF6f/f mice (Figure
3.8E).
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3.3.7 Muscle-specific depletion of TRAF6 increases fibrosis in 9-month old mdx mice.
Fibrosis is a pathogenic factor characterized by chronic inflammation with persistent
production of profibrotic cytokines and excessive deposition of ECM proteins, including
collagens and fibronectin which can impair tissue function (124). Fibrosis is also a major
pathological feature in muscular dystrophy which progressively deteriorates locomotor
capacity, posture maintenance, and the vital function of respiratory muscles (125).
Progressive fibrosis is observed in diaphragm of the mdx mice which recapitulates clinical
signs of DMD patients (115). We measured level of fibrosis by performing Trichrome
staining on diaphragm and GA muscle sections. Accumulation of collagens was
significantly increased in both diaphragm and GA muscle of 9-month old mdx;TRAF6mko
mice compared with age-matched mdx;TRAF6f/f littermates (Figures 3.9A, 3.9B). We next
sought to investigate whether the deterioration in muscle histopathology observed in 9month old mdx;TRAF6mko mice is reflected in muscle function. Indeed, forelimb grip
strength and total limb grip strength of mdx;TRAF6mko mice were found to be significantly
reduced compared with littermate mdx;TRAF6f/f mice (Figures 3.9C, 3.9D). Together, these
results demonstrate that continued inhibition of TRAF6 exacerbates pathology and caused
loss of muscle strength in old mdx mice.

3.3.8 Inhibition of TRAF6 reduces the markers of autophagy in dystrophic muscle of
mdx mice. Recent studies have shown that inhibition of autophagy is one of the major
causes for myopathy in various models of muscular dystrophy including mdx mice (111).
Since TRAF6 is an important positive regulator of autophagy, we next sought to determine
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whether the inhibition of TRAF6 further represses autophagy in mdx mice. Elevation in the
level of LC3B-II protein is a hallmark of autophagy (106). We measured levels of LC3B-I
and LC3B-II protein in skeletal muscle of mdx;TRAF6f/f and mdx;TRAF6mko mice. The
levels of LC3B-II were significantly reduced in skeletal muscle of 6-week mdx;TRAF6mko
mice compared with mdx;TRAF6f/f mice (Figures 3.10A, 3.10B). Moreover, the levels of
another autophagy-related protein Beclin1 were significantly reduced in myofibers of
mdx;TRAF6mko mice compared with mdx;TRAF6f/f mice (Figures 3.10A, 3.10B). p62
protein undergoes degradation through autophagy-lysosomal system (41, 106). To further
confirm the role of TRAF6 in induction of autophagy in myofiber of mdx mice, we also
measured the levels of p62 protein. Results showed that levels of p62 protein were
significantly higher in skeletal muscle of mdx;TRAF6mko mice compared with
mdx;TRAF6f/f littermates (Figures 3.10A, 3.10B).
TRAF6 has also been shown to induce the expression of ubiquitin-proteasome
system (UPS) and autophagy-related molecules in skeletal muscle in many catabolic
conditions (41, 43). To understand whether TRAF6 regulates the expression of the
components of UPS and autophagy in dystrophic muscle, we performed QRT-PCR assay.
Our results showed that the mRNA levels LC3B, Beclin1, and Atrogin-1 are significantly
reduced in dystrophic muscle of 9-month old mdx;TRAF6mko mice compared with
mdx;TRAF6f/f mice (Figure 3.10C). Together these results suggest that the inhibition of
TRAF6 represses autophagy and UPS which may be responsible for accumulation of
damaged proteins and organelles leading to increased myopathy at later stages of disease
progression in mdx mice.
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3.3.9 Inhibition of TRAF6 reduces the activation of Akt in dystrophic muscle of mdx
mice. Previous studies have shown that the Akt-mTOR signaling pathway inhibits
autophagy in skeletal muscle (106). There is also evidence that TRAF6 activates Akt in
some cell types (36). Moreover, it has been also reported that the activity of Akt-mTOR
pathway is increased in skeletal muscle of mdx mice compared to wild-type controls (18,
126). We investigated whether TRAF6 affects the activation of Akt in skeletal muscle of
mdx mice. Protein extracts prepared from GA muscle of mdx;TRAF6f/f and mdx;TRAF6mko
mice were subjected to immunoblotting to detect phosphorylated and total protein levels of
Akt, mTOR, and p70S6 kinase. Results showed that the phosphorylation of Akt, mTOR, and
p70S6 kinase was significantly reduced in myofibers of mdx;TRAF6mko compared to
mdx;TRAF6f/f mice (Figure 3.11A, 3.11B). Collectively these results indicate that TRAF6
is involved in the activation of Akt; however, TRAF6 regulates autophagy independent of
Akt signaling.

3.4 DISCUSSION
Recent studies using genetic mouse models and pharmacological approaches have provided
strong evidence that the modulation of activity of specific signaling pathways has enormous
potential to reduce the severity of disease progression in muscular dystrophy (16, 17, 127).
While the role of anomalous myogenic signaling has become increasingly clear, the
proximal signaling events which lead to the activation of different pathways in dystrophic
muscle remain less understood. Furthermore, the effect of long-term inhibition of different
signaling pathway in disease progression in models of DMD has not been yet investigated.
Since TRAF6 is an important upstream regulator of many proinflammatory signaling
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pathways, we investigated the role of TRAF6 in pathogenesis of DMD. Our study
demonstrates that the expression and activity of TRAF6 are increased in dystrophindeficient skeletal muscle (Figure 3.1). While muscle-specific depletion of TRAF6 signaling
reduces injury and improves muscle histopathology (Figure 3.4) and regeneration (Figure
3.7) in young mice (7-8 weeks), long-term inhibition of TRAF6 results in deterioration of
myopathy and loss of function in mdx mice (Figures 3.8 and 3.9).
One of the mechanisms by which muscle-derived TRAF6 signaling causes dystrophy
in young mdx mice is by promoting chronic inflammatory response. Initial fiber necrosis
due to sarcolemmal instability causes severe inflammatory response in skeletal muscle
which includes infiltration of macrophages and neutrophils in dystrophic muscle and
increased levels of proinflammatory cytokines leading to hastening of fiber necrosis and
disease progression in DMD (17, 127). Muscle-derived factors appear to be some of the
important contributors of chronic inflammation in mdx myofibers supported by the findings
that the activation of proinflammatory transcription factors such as NF-κB and activator
protein-1 (AP-1) and levels of various inflammatory cytokines (e.g. TNF-α and IL-1β) start
increasing before the onset of fiber necrosis (16, 18, 20, 21). Our results demonstrate that
muscle-specific inhibition of TRAF6 leads to diminished activation of NF-κB in dystrophic
muscle of young mdx mice (Figure 3.6C, 3.6D). It is notable that in addition to
proinflammatory cytokines, NF-κB also induces the expression of a number of chemokines
which causes extravasation and migration of leukocytes (77, 121). Consistently, we have
found that the accumulation of macrophages and transcript levels of inflammatory cytokines
were also significantly reduced in skeletal muscle of mdx;TRAF6mko mice compared to
mdx;TRAF6f/f mice (Figure 3.6). These results are consistent with previous reports
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demonstrating that muscle-specific depletion of TRAF6 inhibits activation of NF-κB in the
conditions of denervation and cancer cachexia and cardiotoxin-mediated muscle injury (41,
84). Although depletion of TRAF6 in skeletal muscle reduces inflammation, in the present
study, we have not investigated the role of TRAF6 in immune cells. It is possible that
TRAF6 signaling emanating from immune compartments might also contribute to the
inflammatory processes in dystrophic muscles and concurrent inhibition of TRAF6 in
skeletal muscle and immune cells may lead to further improvement in dystrophinopathy.
Future research should clarify the role of the TRAF6 signaling in immune cells in
pathogenesis of DMD.
Another mechanism by which TRAF6 signaling causes dystrophy is through the
repression of myofiber regeneration. Inhibition of TRAF6 increases the formation of new
myofibers in mdx mice (Figures 3.7). These results are in agreement with our previous
findings demonstrating that the depletion of TRAF6 improves whereas its overexpression
represses the regeneration of myofiber in response to acute injury in wild-type mice (84).
Muscle regeneration after injury is a complex process which involves the activation of
quiescent satellite cells, their differentiation into myoblasts, and finally fusion of myoblasts
to damaged myofibers (1, 3). Although the exact mechanisms remain enigmatic, the results
of the present study suggest that TRAF6 signaling from injured myofibers limit the
activation of satellite cells and may interfere with their differentiation and fusion into
myotubes. It has been consistently observed that inflammatory cytokines such as TNF-α, IL1β, and IL-6 inhibit the differentiation of myoblasts by repressing the levels of MyoD (76,
113, 128-130). Furthermore, there is a positive feed-back loop between inflammatory
cytokines and NF-κB transcription factor. Elevated levels of inflammatory cytokines
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activate NF-κB, which in turn induces the expression of inflammatory cytokines leading to
sustained activation of NF-B (77, 121). Acharyya et al have previously reported that NFκB inhibits myofiber regeneration in mdx mice (16). Our results demonstrate that TRAF6 is
an upstream activator of NF-κB and expression of inflammatory cytokines in dystrophic
muscle (Figure 3.6). Therefore, it is reasonable to speculate that the inhibition of TRAF6
improves muscle regeneration through blocking NF-κB and reducing repertoire of
inflammatory cytokines in dystrophic muscle.
A striking observation of the present study is that the long-term inhibition of TRAF6
signaling exacerbates muscle pathology in mdx mice. Analysis of myofibers of 9-month old
mdx;TRAF6mko mice revealed the presence of significantly increased number of necrotic
fibers and replacement of muscle fibers by collagens (Figures 3.8 and 3.9). Although the
exact mechanisms remain enigmatic, inhibition of autophagy appears to be one of the
important reasons for increased myopathy in mdx;TRAF6mko mice. Autophagy is an
important homeostasis mechanism which is critical for clearing dysfunctional organelles and
to preventing tissue damage (106, 131). Recently, the role of autophagy in pathogenesis of
muscular dystrophy has been investigated using multiple approaches. Autophagy has been
found to be impaired in muscle biopsies from patients with DMD and in mdx mice with
concomitant accumulation of damaged organelles (111). Notably, reactivation of autophagy
by feeding low-protein diet improved muscle strength and various pathological features
including fiber necrosis, pathological hypertrophy, and fibrosis in mdx mice (111).
Similarly, forced activation of autophagy using AMPK agonist, AICAR (5-aminoimidazole4-carboxamide-1-β-d-ribofuranoside) led to improvements in mdx diaphragm
histopathology and in force-generating capacity (132).
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TRAF6 is an essential component of autophagy in mammalian cells. TRAF6
interacts with LC3B through p62. It has been recently demonstrated that TRAF6 causes the
Lys-63–linked ubiquitination of Beclin1 (the mammalian homologue of yeast Atg6), which
is essential for autophagosome formation in response to Toll-like receptor 4 signaling (46).
We have previously reported that muscle-specific depletion of TRAF6 inhibits expression of
autophagy-related molecules and autophagosome formation in atrophying skeletal muscle
(41, 43). Our results demonstrate that the levels of autophagy markers are considerably
reduced in dystrophic muscle of mdx;TRAF6mko compared to mdx;TRAF6f/f mice
suggesting that TRAF6 is required for the activation of autophagy in mdx mice (Figures
3.10A, 3.10B). While autophagy is also inhibited in young mdx;TRAF6mko mice, there is
still significant improvement in muscle pathology compared with mdx;TRAF6f/f littermates.
We envision that inflammation plays a predominant role in initial muscle injury and
regeneration and that there may not be sufficient load of damaged organelles to clear
through autophagy pathway in young mdx mice. It is notable that excessive autophagy
causes muscle wasting in many catabolic states (106). Thus the initial inhibition of
autophagy in young mdx;TRAF6mko mice may be a protective mechanism to preserve
skeletal muscle mass. However, due to the progressive nature of myopathy in mdx mice,
autophagy becomes essential for clearance of defunct cellular organelles at later stages and
hence continued inhibition of autophagy exaggerates dystrophic phenotype in mdx mice.
Moreover, our results demonstrate that depletion of TRAF6 inhibits both NF-B and Akt
signaling in skeletal muscle of mdx mice (Figures 3.6C, 3.6D, 3.11A, 3.11B). While
specific inhibition of NF-B has been shown to ameliorate dystrophy in young mdx mice
(16), the effects of long-term inhibition of NF-B have not been yet investigated. Both NF-
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B and Akt are known to play critical roles in cell survival mechanisms (121, 133).
Therefore, it is possible that prolonged inhibition of NF-B and Akt in mdx;TRAF6mko mice
also directly induces muscle cell death. Indeed, it has been previously reported that forced
activation of Akt prevents myofiber degeneration and improves regeneration in mdx mice
(134).
Akt signaling is also an important regulator of autophagy in skeletal muscle.
Activation of Akt inhibits autophagy through repressing the activity of FOXO family
transcription factors (106). Recently, De Palma et al. have suggested that the activation of
Akt signaling is responsible for inhibition of autophagy in mdx mice (111). However, our
results demonstrate that TRAF6 regulates autophagy independent of Akt signaling. Musclespecific inhibition of TRAF6 also inhibited Akt pathway in myofibers of mdx mice (Figures
3.11A, 3.11B). It is also notable that the inhibition of TRAF6 signaling did not affect the
activation of Akt kinase in regenerating myofibers in response to cardiotoxin-mediated
injury (84). However, in some other cell types, TRAF6 has been found to be an important
upstream activator of Akt kinase (36). Together these findings further highlight the role of
TRAF6 in context-dependent activation of various signaling pathways.
In summary, our study has provided novel mechanistic insights in dystrophic
progression by identifying the role of TRAF6 in mdx mice. It is now increasingly clear that
muscular dystrophy is a complex disorder and that a single therapeutic intervention may not
be sufficient to treat patients with muscular dystrophy. Recent studies further support this
notion by providing experimental evidence that combinatorial approaches correcting more
than one parameter of pathological cascade can produce more robust improvement in
myopathy in mouse models of muscular dystrophy (135). Our results demonstrate that the
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inhibition of TRAF6 is effective in reducing inflammatory response and initial fiber necrosis
in mdx mice. However, it is also evident that the inhibition of TRAF6 can also produce
deleterious effects due to further repression of autophagy in dystrophic muscle.
Nevertheless, it is reasonable to speculate that a combinatorial approach involving
pharmacological inhibitors of TRAF6 and activators of autophagy can provide an effective
treatment strategy for patients with DMD.
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FIGURE 3.1

70

FIGURE 3.1. Activation of TRAF6 in skeletal muscle of mdx mice. Levels of TRAF6
protein in (A) Diaphragm and (B) Gastrocnemius muscle of wild-type (WT) and mdx mice
at different stages of development measured by Western blotting. Representative
immunoblots and densitometry quantification of data are presented here. (C) Diaphragm
extracts from 10, 14, 21, 23 and 48-day old WT and mdx mice were immunoprecipitated
with anti-ubiquitin followed by Western blotting using anti-TRAF6. Representative
immunoblot and quantification of fold change in the levels of ubiquitinated TRAF6 protein
are depicted here. N=3 or 4 at indicated age of mice. Error bars represent SD. *p < 0.05,
values vary significantly from corresponding age-matched WT mice.
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FIGURE 3.2

FIGURE 3.2. Levels of TRAF6 in skeletal muscle of young and old WT and mdx mice.
Representative immunoblots and densitometry quantification demonstrating that TRAF6
protein levels are upregulated in quadriceps muscle of (A) 6-week old and (B) 9-month old
mdx mice compared with aged-matched WT mice. N=3 in each age group. Error bars
represent SD. *p < 0.05, values vary significantly from corresponding age-matched WT
mice.
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FIGURE 3.3
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FIGURE 3.3. Targeted depletion of TRAF6 improves muscle strength in 7-week old
mdx mice. (A) Western blot analysis of TRAF2, TRAF3, and TRAF6 protein levels in
diaphragm and gastrocnemius (GA) muscle of 2-week old mdx;TRAF6f/f and
mdx;TRAF6mko mice. (B) Densitometry quantification of TRAF6 levels in diaphragm and
GA muscle of 2-week old mdx;TRAF6f/f and mdx;TRAF6mko mice. N=4 in each group. (C)
Representative photomicrographs of H&E-stained GA muscle sections of 2-week old
mdx;TRAF6f/f and mdx;TRAF6mko mice. Scale bar: 20µm. Muscle strength was evaluated
through a series of functional tests in 7-week old mdx;TRAF6f/f and mdx;TRAF6mko mice.
Bar diagrams represent (D) Fore limb grip strength normalized to body weight; (E) Total
four limb grip strength; and (F) Wire hanging time (in seconds). N=8 in each group. Error
bars represent SD. *p < 0.05, values vary significantly from mdx;TRAF6f/f littermate.
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FIGURE 3.4
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FIGURE 3.4. Depletion of TRAF6 improves muscle histopathology in 7-week old mdx
mice. (A) Skeletal muscle of 7-week old mdx;TRAF6mko and littermate mdx; TRAF6f/f mice
were isolated and processed for H&E staining. Representative photomicrographs of H&Estained diaphragm (top), GA (middle) and quadriceps (bottom) muscles displaying
manifestations of pathology. Scale bar: 20 µm. (B) Percentage necrotic area in quadriceps
muscle of 7-week old mdx;TRAF6f/f and mdx;TRAF6mko littermates. (C) Percentage of
fibers with one or more centrally localized nuclei in quadriceps muscle of 7-week old
mdx;TRAF6f/f and mdx;TRAF6mko mice. (D) Relative fold change in creatine kinase (CK)
activity in serum of 7-week old mdx;TRAF6f/f and mdx;TRAF6mko mice. N=7 in each
group. Error bars represent SD. *p < 0.05, values vary significantly from mdx;TRAF6f/f
mice.
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FIGURE 3.5

FIGURE 3.5. Deletion of TRAF6 reduces sarcolemmal injury in mdx mice. (A)
Quadriceps muscle sections from 7-week old mdx;TRAF6f/f and mdx;TRAF6mko mice were
immunostained with Cy3-labeled goat anti-mouse IgG to detect permeable/damaged fibers.
Representative photomicrographs are presented here. (B) Quantification of IgG-positive
fibers in quadriceps muscle sections from 7-week old mdx;TRAF6f/f and
mdx;TRAF6mko mice. N=7 in each group. Scale bar: 20μm. Error bars represent SD. *p <
0.05, values vary significantly from mdx;TRAF6f/f mice.
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FIGURE 3.6

78

FIGURE 3.6. Muscle-specific depletion of TRAF6 attenuates inflammatory processes
in dystrophic muscle of 7-week old mdx mice. (A) Representative photomicrographs
demonstrating F4/80+ macrophages in diaphragm section of 7-week old mdx;TRAF6f/f and
mdx;TRAF6mko mice. Scale bar: 20µm. (B) Quantification of F4/80+ cells in diaphragm of
7-week old mdx;TRAF6mko and mdx; TRAF6f/f mice. N=7 or 8 in each group. (C)
Representative EMSA gels presented here demonstrate that the DNA-binding activity of
NF-κB is reduced in diaphragm (upper panel) and quadriceps (lower panel) muscle in 7week-old mdx;TRAF6mko mice compared to littermate mdx; TRAF6f/f mice. (D)
Quantification of fold change in DNA-binding activity of NF-B in diaphragm and
quadriceps muscle of 7-week old mdx;TRAF6mko mice and mdx; TRAF6f/f littermates.
N=3 in each group. (E) Relative mRNA levels of IL-1β, IL-6, TNFα and MMP-9 measured
by QRT-PCR in diaphragm of 7-week old mdx; TRAF6f/f and mdx;TRAF6mko mice. N= 4 in
each group. Error bars represent SD. *p < 0.05, values significantly different from littermate
mdx;TRAF6f/f mice.
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FIGURE 3.7

B
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FIGURE 3.7. Depletion of TRAF6 improves myofiber regeneration in young mdx mice.
(A) Quadriceps muscle from 7-week-old mdx;TRAF6f/f and mdx;TRAF6mko mice were
isolated and processed for e-MyHC (top) and Pax7 (bottom) staining. Nuclei were identified
by co-staining with DAPI. Representative photomicrographs are presented here. Arrows
point to Pax7+ cells. (B) Quantification of mean minimum Feret (MinFeret) diameter of
eMyHC+ fibers in quadriceps muscle of mdx;TRAF6f/f and mdx;TRAF6mko mice. (C)
Average number of Pax7+ cells per field (~0.15 mm2) in quadriceps muscle of 7-week old
mdx;TRAF6f/f and mdx;TRAF6mko mice. N=8 in each group. Scale bar: 20μm. Error bars
represent SD. *p < 0.05, values significantly different from mdx;TRAF6f/f mice.
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FIGURE 3.8
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FIGURE 3.8. Inhibition of TRAF6 exacerbates myopathy in 9-month old mdx mice.
Diaphragm and GA muscles were isolated from 9-month old mdx; TRAF6f/f and
mdx;TRAF6mko mice and processed for H&E staining. (A) Representative photomicrographs
of H&E-stained transverse sections of diaphragm (top) and GA (bottom) muscle. Scale bar:
20 µm. (B) Percentage area under necrosis in H&E-stained sections of GA muscle of 9month old mdx;TRAF6f/f and mdx;TRAF6mko littermates. (C) Quantification of variability in
fiber cross-sectional area (CSA) in GA muscle of 9-month old mdx;TRAF6f/f and
mdx;TRAF6mko mice. (D) GA muscle sections from 9-month old mdx;TRAF6f/f and
mdx;TRAF6mko mice were immunostained with Cy3-labeled goat anti-mouse IgG to detect
permeable/damaged fibers. Representative photomicrographs are presented here. (E)
Quantification of IgG-positive fibers in GA muscle sections from 9-month old
mdx;TRAF6f/f and mdx;TRAF6mko mice. N=7 or 8 in each group. Scale bar: 20μm. Error
bars represent SD. *p < 0.05, values vary significantly from mdx;TRAF6f/f mice.
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FIGURE 3.9

FIGURE 3.9. Muscle-specific depletion of TRAF6 increases fibrosis in 9-month old
mdx mice. (A) Diaphragm and GA muscle were isolated from 9-month old mdx; TRAF6f/f
and mdx;TRAF6mko mice and transverse muscle sections made were processed for Mason's
Trichrome staining for detection of collagen accumulation. Representative
photomicrographs are presented here. Scale bar: 20µm. (B) Quantification of fibrotic area in
diaphragm and GA muscle of 9-month old mdx;TRAF6f/f mice and mdx;TRAF6f/f
littermates. Muscle strength of 9-month old mdx;TRAF6f/f and mdx;TRAF6mko mice was
evaluated. Bar diagrams representing (C) forelimb grip strength and (D) total four limb grip
strength normalized to body weight. N=8 in each group. Scale bar: 20μm. Error bars
represent SD. *p < 0.05, values significantly different from mdx; TRAF6f/f mice.
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FIGURE 3.10
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FIGURE 3.10. Depletion of TRAF6 in inhibits autophagy in mdx mice. (A)
Representative immunoblots present here demonstrate the levels of LC3B I and LC3B II and
Beclin1, p62, and an unrelated protein GAPDH (glyceraldehyde 3-phosphate
dehydrogenase). (B) Densitometry quantification of LC3B I & II, Beclin1, and p62 protein
levels in GA muscle of 6-week old mdx;TRAF6f/f and mdx;TRAF6mko mice. N=6 in each
group. Error bars represent SD. *p < 0.05, values significantly different from mdx;TRAF6f/f
mice. Relative mRNA levels of autophagy related genes (LC3B, Beclin1 and p62) and
ubiquitin-proteasome system-related genes (Atrogin-1 and MuRF1) measured by QRT-PCR
in quadriceps muscle of (C) 7-week old and (D) 9-month old mdx;TRAF6f/f and
mdx;TRAF6mko mice. N= 4 in each age group. Error bars represent SD. *p < 0.05, values
significantly different from littermate mdx;TRAF6f/f mice.
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FIGURE 3.11

FIGURE 3.11. Role of TRAF6 in activation of Akt signaling pathway in mdx mice. GA
muscle of 6-week old mdx;TRAF6f/f and mdx;TRAF6mko mice were processed for Western
blotting. (A) Representative immunoblots present here demonstrate the levels of
phosphorylated (p) and total Akt, mTOR, p70 S6 kinase (p70 S6K), and GAPDH protein.
(B) Quantification of phosphorylated versus total Akt, mTOR, p70 S6K ratio in GA muscle
of 6-week old mdx;TRAF6f/f and mdx;TRAF6mko mice. N=6 in each group. Error bars
represent SD. *p < 0.05, values significantly different from mdx;TRAF6f/f mice.
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CHAPTER 4
TRAF6 IS CRITICAL FOR SATELLITE CELL FUNCTION AND
SKELETAL MUSCLE REGENERATION UPON INJURY
4.1. INTRODUCTION
Satellite cells are skeletal muscle resident stem cells which reside between the plasma
membrane and basal lamina in a quiescent state characterized by low-metabolic activity and
reversible mitotic arrest (136). These cells are primarily responsible for growth,
maintenance, and repair of injured adult myofibers (3, 137). In response to myofiber injury,
satellite cells are rapidly activated to reenter the cell cycle, undergo proliferation, and
differentiate into myoblasts which eventually fuse with each other or pre-existing myofibers
to complete the repair process (138, 139). While most of the activated satellite cells
differentiate into myogenic lineage, a small portion of them self-renew and return to
quiescent state to respond to next round of muscle injury and repair (138, 139).
Paired-box transcription factor Pax7 is a critical regulator for satellite cell
biogenesis, survival, specification, and self-renewal. Skeletal muscle of Pax7-null mice lack
satellite cells and show reduced muscle growth and defects in regenerative response after
injury (82, 87). Furthermore, quiescent satellite cells express high level of Pax7 whereas the
expression of other myogenic regulatory factors such as Myf5 and MyoD is undetectable. In
proliferating satellite cells, Pax7 persist at lower levels whereas expression of Pax7 is
completely repressed in myogenic lineage cells which commit to terminal differentiation
(64, 138, 140). The critical role of Pax7 in maintaining satellite cell quiescence or self-
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renewal is also evident by the findings that forced expression of Pax7 inhibits myogenesis
and cell cycle progression in satellite cells resulting in the maintenance of their inactivated
state (141). In addition to its imperative role in maintaining the pool of quiescent satellite
cells (142), a temporal expression of Pax7 is also required for sustaining the myogenic
potential of activated satellite cells to drive the events of muscle regeneration (143, 144).
Genetic deletion of Pax7 in satellite cells of adult mice led to failure of myofiber
regeneration due to precocious differentiation (144).
A number of factors have now been identified which regulate satellite cell
homeostasis through modulating the myogenic activity of Pax7. For example, arginine
methyltransferase Carm1 has been found to methylate multiple arginine residues in the N
terminus of Pax7. Methylated Pax7 then recruits the ASH2L:MLL1/2:WDR5:RBBP5
histone H3K4 methyltransferase complex to the promoter region of Myf5 leading to the
induction of Myf5 during satellite stem cell asymmetric division and entry into the
myogenic program (145, 146). Furthermore, both Pax7+/Myf5⁻ satellite stem cells and
Pax7+/Myf5+ committed myogenic precursors express EZH2, the enzymatic subunit of the
Polycomb-repressive complex 2 (PRC2). Conditional deletion of Ezh2 in satellite cells of
mice results in reduced number of Pax7+ cells and diminished regeneration of injured
skeletal muscle signifying that Ezh2 is essential to maintaining satellite cell pool in adult
skeletal muscle (147). Furthermore, post-transcriptional mechanisms involving microRNAs
(miRs) are involved in the repression of Pax7 during the transition from proliferating
satellite cells to differentiating satellite cells. In particular, miR-1 and miR-206, which are
highly up-regulated during satellite cell differentiation, bind to the 3' untranslated region of
Pax7 transcript to repress the levels of Pax7 (148). While it is increasingly clear that both
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protein modifications and post-transcriptional mechanisms (e.g. miRs) regulate Pax7
activity, the molecular mechanisms which govern the gene expression of Pax7 in satellite
cells remain largely unknown.
Several lines of evidence suggest that Notch signaling plays a critical role in selfrenewal and differentiation of satellite cells (2, 74, 84, 137). Overexpression of Notch 1
intracellular domain (N1ICD) increases self-renewal of satellite cells on cultured myofibers
(149). Activation of Notch pathway also inhibits differentiation through repressing the levels
of MyoD (150). Moreover, a γ-secretase inhibitor reduces the proportion of Pax7+/MyoDcells and increases Pax7-/MyoD+ cells on cultured myofibers (64, 84). Furthermore,
inactivation of RBP-Jk through genetic approach dramatically reduces the proportion of
Pax7+ cells by spontaneously increasing terminally differentiated cells in both normal and
injured skeletal muscle of mice (72, 73). It has been found that N1ICD stimulates the
expression of Pax7 through interaction with RBP-Jκ, which binds to two consensus sites in
the promoter region of Pax7 gene (149). Moreover, signaling through the Wnt7a/Fzd7
planar-cell-polarity pathway drives the symmetric expansion satellite stem cell to enhance
regeneration of injured myofibers (151). Finally, angiotensin-1 produced by fibroblasts and
vascular cells binds to Tie-2 receptor on satellite cells to stimulate ERK pathway leading to
increased number of quiescent satellite cells (152). However, it remains unknown whether
there are additional pathways which regulate the abundance of satellite stem cells in skeletal
muscle.
Tumor necrosis factor (TNF) receptor-associated factor (TRAF6) is a crucial adaptor
protein that mediates signaling events from TNF receptor superfamily (TNFRSF),
interleukin-1 receptor (IL-1R) family, and toll-like receptor (TLR) family (27). TRAF6 is
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also a non-conventional RING finger E3 ligase, which catalyzes formation of K63-linked
ubiquitin chains (33, 36). Signals coupled through TRAF6 lead to activation of a cascade
resulting in the activation of nuclear factor-κB (NF-κB) and activator protein 1 (AP1)
transcription factors, through activation of upstream kinases, including inhibitor of kappa B
kinase (IKK) and the mitogen-activated protein kinase (MAPKs, i.e. ERKs, JNKs, and
p38MAPK) family (27, 33, 36, 153). TRAF6 plays critical roles in innate immune responses
and regulate the function of antigen-presenting cells such as macrophages and dendritic cells
and the CD40-induced B cell responses (81, 153). TRAF6-deficinet mice die between 2-3
weeks due to severe osteopetrosis and deficit of tooth eruption because of defective
signaling through the receptor activator of NF-B (RANK), a member of TNF receptor
superfamily which is required for osteoclast formation (44, 45). TRAF6-deficinet mice also
show significant hematopoietic abnormalities (154). Furthermore, TRAF6 has also been
found to play crucial role in a lymph node organogenesis, formation of skin appendices, and
development of nervous system (153). While TRAF6 is expressed in the cells of myogenic
lineage (41, 42, 84, 103), the role of TRAF6 in satellite stem cell homeostasis and function
has not been yet investigated.
In this study, using a conditional knockout approach we have investigated the role of
TRAF6 in regulation of satellite stem cell homeostasis. Our results demonstrate TRAF6 is
critical for the gene expression of Pax7, maintaining the satellite stem cell pool, and
regeneration of injured skeletal muscle. The ablation of TRAF6 in satellite cells of mdx
mice (a model for Duchenne muscular dystrophy) exaggerates dystrophic phenotype due to
impairment in myofiber regeneration. Furthermore, our results demonstrate that TRAF6mediated signaling is required for the activation of ERK and JNK which causes the
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phosphorylation of transcription factor c-Jun which in turn binds to the proximal region of
Pax7 promoter to augment the gene expression of Pax7.

4.2. MATERIALS AND METHODS
Animals. Satellite cells specific TRAF6-knockout mice (henceforth TRAF6scko) were
generated by crossing Pax7CreER mice (Jax Strain: B6;129-Pax7tm2.1(cre/ERT2)Fan/J) with floxed
TRAF6 (i.e. TRAF6f/f) mice. Similarly, mdx mice were crossed with TRAF6scko to generate
mdx;TRAF6scko mice and littermate mdx;TRAF6f/f mice. All mice were in the C57BL6
background and their genotype was determined by PCR from tail DNA. Tamoxifen
administration was started at 6 weeks of age and the mice were maintained on tamoxifen
diet during the duration of the experiment. At the age of 8 weeks, 100 µl of 1.2% BaCl2
(Sigma Chemical Co.) dissolved in phosphate-buffered saline (PBS) was injected into the
TA muscle of mice to induce necrotic injury. At various time points, TA muscle was
collected from euthanized mice for biochemical and histology studies. All experimental
protocols with mice were approved in advance by the Institutional Animal Care and Use
Committee (IACUC) at the University of Louisville.

Histology and Morphometric Analysis. Hind limb muscle from mice were isolated and
frozen in isopentane cooled in liquid nitrogen and sectioned in a microtome cryostat. For the
assessment of tissue morphology, 10µm thick transverse sections of tibial anterior (TA)
muscle were stained with Hematoxylin and Eosin (H&E) and examined under Nikon Eclipse
TE 2000-U microscope (Nikon). Fiber cross-sectional area (CSA) was analyzed in H&Estained TA muscle sections using Nikon NIS Elements BR 3.00 software (Nikon). For each
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muscle, the distribution of fiber CSA was calculated by analyzing 200 to 250 myofibers as
described (41). The extent of fibrosis in transverse cryosections of TA muscle determined
using Masson’s Trichrome staining kit following a protocol suggested by the manufacturer
(Richard-Allan Scientific).

Indirect Immunofluorescence: For immunohistochemistry study, frozen TA muscle
section sections or paraformaldehyde-fixed cultured myotubes were blocked in 1% bovine
serum albumin in PBS for 1h, and incubated with anti-Pax7 (1:20, Developmental Studies
Hybridoma Bank, DSHB, University of Iowa, Iowa City, IA), anti-E-MyHC (1:50, DSHB,
University of Iowa, Iowa City, IA), anti-MF20 (1:250, DSHB, University of Iowa, Iowa
City, IA) in blocking solution at 4C overnight under humidified conditions. The sections
were washed briefly with PBS before incubation with Alexa Fluor® 488 or 594-conjugated
secondary antibody (1:3000, Invitrogen) for 1h at room temperature and then washed 3
times for 30 minutes with PBS. The slides were mounted using fluorescence medium
(Vector Laboratories) and visualized at room temperature on Nikon Eclipse TE 2000-U
microscope (Nikon), a digital camera (Nikon Digital Sight DS-Fi1), and Nikon NIS
Elements BR 3.00 software (Nikon). Image levels were equally adjusted using Abode
Photoshop CS2 software (Adobe).

Isolation, Culture, and Staining of Single Myofibers. Single myofibers were isolated from
the extensor digitorum longus (EDL) muscles after digestion with collagenase A (Sigma
Chemical Company) and trituration as previously described (83, 84). Suspended fibers were
cultured in 60-mm horse serum-coated plates in Dulbecco's modified Eagle's medium
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supplemented with 10% fetal bovine serum (FBS; Invitrogen), 2% chicken embryo extract
(Accurate Chemical, Westbury, NY), and 1% penicillin-streptomycin for 3 days. Freshly
isolated fibers and cultured fibers were then fixed in 4% PFA and stained for Pax7 and
MyoD.

Satellite Cell Cultures. Satellite cells were isolated from the hind limbs of 8-week-old
mice following a protocol as described (22). Briefly, mice were sacrificed and TA and
gastrocnemius muscles were isolated. Excess connective tissues and fat were cleaned in
sterile PBS followed by mincing of skeletal muscle in DMEM and enzymatic dissociation
with 0.1% Pronase. The digested slurry was spun, pelleted, and triturated several times and
then passed through a 70-μm cell strainer (BD Falcon). The filtrate was spun at 1000
× g and resuspended in myoblast growth medium (Ham's F-10 medium with 20% FBS
supplemented with 5 ng/ml of basic fibroblast growth factor). Cells were first re-fed after 3
days of initial plating. During the first few passages, cells were also enriched by pre-plating
for selection of pure myoblast population. Upon selection, the cells were cultured in a 1:1
ratio of myoblast growth medium and growth medium (DMEM with 20% FBS) until 80%
confluence was reached.

Cell Proliferation Assay. Satellite cell proliferation was assayed using Click-iT® EdU
Cell Proliferation Assay kit (Invitrogen). In brief, satellite cells were seeded on 24-well cell
culture plates coated with 10% Matrigel. 5-Ethynyl-2′-deoxyuridine (10 μM, Invitrogen)
was added in culture medium for the 90 minutes. Cells were then fixed with 3.7%
paraformaldehyde for 15 min and permeabilized with 0.5% Triton X-100. The 5-ethynyl-2′-
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deoxyuridine+ cells were identified using Click-iT reaction mixture. Nuclei were
counterstained with 1× Hoechst 33342 for 30 min at room temperature. Images were
visualized on Nikon Eclipse TE 2000-U microscope (Nikon), a digital camera (Nikon
Digital Sight DS-Fi1), and analyzed using Nikon NIS Elements BR 3.00 software (Nikon).

Generation of short hairpin RNA (shRNA) constructs. The pLKO.1-mCherry-Puro
plasmid was kindly provided by Dr. Renzhi Han of Loyola University. The shRNA
oligonucleotides were synthesized to contain the sense strand of target sequences for
TRAF6, short spacer (AACG or TTCAAGAGA) and the reverse complement sequences
followed by five thymidines as an RNA polymerase III transcriptional stop signal.
Oligonucleotides were annealed and cloned into pLKO.1-mCherry-Puro with AgeI/EcoRI
sites. The insertion of shRNA sequence was confirmed by sequencing of the plasmid.

Gene Transfer by Electroporation. To overexpress specific proteins in primary satellite
cells, plasmid DNA was introduced into cells by electroporation (1500 V, 10 ms for
duration, 3 pulses) using the Neon transfection system following a protocol suggested by
the manufacturer (Invitrogen).

Western Blot. Quantitative estimation of specific protein was performed by Western blot
using a method as described (41, 50). TA muscle were washed with PBS and homogenized
in lysis buffer [50 mM Tris-Cl (pH 8.0), 200 mM NaCl, 50 mM NaF, 1 mM dithiotheritol
(DTT), 1 mM sodium orthovanadate, 0.3% IGEPAL, and protease inhibitors].
Approximately, 100 μg protein was resolved on each lane on 8-10 % SDS-PAGE,
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electrotransferred onto nitrocellulose membrane and probed using anti-TRAF6 (1:1000,
Millipore), anti-Pax7 (1:1000, Developmental Studies Hybridoma Bank), anti-E-MyHC
(1:1000, Developmental Studies Hybridoma Bank), (anti-phospho-c-Jun (Cell Signaling
Technology), anti-c-Jun (Santa Cruz Biotechnology), anti-phospho-ERK1/2 (Cell Signaling
Technology), anti-ERK1/2 (Cell Signaling Technology), anti-phospho-JNK1/2 (Cell
Signaling Technology), anti-JNK1/2 (Cell Signaling Technology), anti-phospho-p38 MAPK
(Cell Signaling Technology), anti-p38 MAPK (Cell Signaling Technology), anti-phosphoERK5 (Cell Signaling Technology), anti-ERK5 and anti-α-GAPDH (1:2000, Cell Signaling,
Inc.) and detected by chemiluminescence.

Fluorescence Activated Cell Sorting (FACS). Satellite were analyzed by FACS as
previously described (64, 83). Approximately 2x106 cells were incubated in DMEM
(supplemented with 2% FBS and 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid)) and dead cells (positive for Propidium iodide staining) which were around ~1% were
excluded from all FACS analysis. For satellite cell quantification from heterogeneous cell
population, cells were immunostained with antibodies against, CD45, CD31, and Ter-119
for negative selection (all PE conjugated, eBiosciences), and with α7-integrin (MBL
International) for positive selection. A tandem conjugate of R-PE (Alexa 647, Molecular
Probes) was used as a secondary antibody against α7-integrin. FACS analysis was
performed on a C6 Accuri cytometer equipped with three lasers. The output data was
processed and plots were prepared using FCS Express 4 RUO software (De Novo Software).
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RNA Isolation and Quantitative Real-time PCR (QRT-PCR). RNA isolation and QRTPCR were performed using a method as previously described (41).

Statistical Analyses. Results are expressed as mean ± standard deviation (SD). Statistical
analyses used Student's t-test to compare quantitative data populations with normal
distribution and equal variance. A value of P < 0.05 was considered statistically significant
unless otherwise specified.

4.3 RESULTS
Ablation of TRAF6 in satellite cells impairs regeneration of injured myofibers in adult
mice. Following acute muscle injury, muscle satellite cells are activated to drive the events
of muscle repair in a manner that mimics embryonic development (1, 4). Our previous study
revealed that the levels of TRAF6 are highly up regulated following muscle injury and the
ablation of TRAF6 under the control of muscle creatine kinase (MCK) promoter (i.e.
TRAF6mko) improves muscle regeneration possibly due to overall reduction in inflammatory
response (84). However, an interesting observation was that while ablation of TRAF6 in
myofibers reduced the levels of TRAF6 in control muscle, TRAF6 protein levels remained
relatively high in contralateral injured muscle of TRAF6mko mice (84) indicating that
myofibers are not the only source for TRAF6 in injured skeletal muscle. TRAF6 is known to
be expressed by a number of other cell types including immune cells (27, 81) and
proliferating myoblasts (41, 42) which occupy injured muscle microenvironment. To
delineate the contribution of satellite cells in the elevated levels of TRAF6 in injured
muscle, we crossed TRAF6f/f mice with tamoxifen inducible Pax7 Cre mice (Pax7CreER
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mice) to generate satellite-cell specific TRAF6-knockout (henceforth, TRAF6scko) mice
(Figure 4.1A). 8-week old littermate TRAF6f/f and TRAF6scko mice were injected
intraperitoneally with tamoxifen (10 mg/mL in corn oil) for four consecutive days and kept
on tamoxifen-containing standard chow (1 mg tamoxifen per day/20g body weight). TA
muscle of these mice then was given intramuscular injection of 100l solution of 1.2%
BaCl2 or saline alone. After 5 days, the levels of TRAF6 were measured by performing
Western blot. Results showed that while injured muscle of TRAF6f/f mice displayed a
dramatic increase in TRAF6 protein levels compared to saline injected control muscle
(Figure 4.1B) as previously described (84), BaCl2-injected muscle of TRAF6scko showed
comparatively smaller up-regulation in the levels of TRAF6 protein (Figure 4.1B)
suggesting that satellite cells are major source of TRAF6 in injured skeletal muscle of mice.
To confirm that TRAF6 is expressed in the satellite cells, primary myogenic cells prepared
from C57BL6 mice were FACS sorted for 7-integrin (a marker for satellite cells) after
eliminating possible infiltrating cells. This analysis showed that TRAF6 is highly enriched
in the 7-integrin+ population (Figure 4.2A). Furthermore, immunohistochemical analysis
showed that TRAF6 is expressed in cultured Pax7+ myogenic cells (Figure 4.2B). To
determine whether there is any correlation in the levels of TRAF6 and Pax7 during
myogenic differentiation, we next measured the protein levels of TRAF6 and Pax7 at
different time points after induction of differentiation in primary cultures. Results showed
that levels of both Pax7 and TRAF6 are repressed and followed similar kinetics after
addition of differentiation medium in cultured satellite cells (Figure 4.2C).
We next investigated the role of TRAF6 in satellite cells during skeletal muscle
regeneration. TA muscle of adult TRAF6f/f and TRAF6scko mice was injured through
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intramuscular injection of 1.2% BaCl2 solution. The muscle was isolated at 3, 5, 10 and 21
days post-BaCl2 injection and analyzed by performing H&E staining. Histological
examination of H&E-stained TA muscle sections revealed equal necrosis of TA muscle of
TRAF6scko and TRAF6f/f mice 3 days post-BaCl2 injection (Figure 4.3A). Strikingly, muscle
regeneration was dramatically reduced in TRAF6scko mice. At day 5 after BaCl2-mediated
injury, newly formed centronucleated fibers populated regenerating TA muscle of TRAF6f/f
mice. By contrast, TA muscle of corresponding TRAF6scko mice showed poor signs of
regeneration evident by reduced myofiber cross-sectional area (CSA) and number of
centronucleated fibers (Figures 4.3A-B) with robust persistence of cellular infiltrate (Figure
4.3A). Manifestations of defective muscle repair in TRAF6scko mice were evident even at 21
days after muscle injury where regenerated muscle of control TRAF6f/f displayed complete
subsidence of inflammatory cells and reconstitution of normal muscle (Figure 4.3A). Signs
of impaired muscle regeneration in TRAF6scko mice were even more pronounced when TA
muscle was subjected to a second round of injury using BaCl2 injection (Figure 4.4A).
Regenerating areas of TRAF6scko muscle were notably void of newly formed muscle fibers
and displayed massive deposition of fibrotic and adipogenic tissue at 5 days of second injury
(Figure 4.4B). These results suggest that TRAF6 is required for satellite cell function during
regenerative myogenesis.

Ablation of TRAF6 in satellite cells impairs myofiber formation upon injury. Proper
muscle regeneration involves differentiation and fusion of proliferating myogenic cells to
restore the architectural structure of the injured muscle. This process involves intrinsic
regulation of transcription factors and expression markers that drive progression of activated
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satellite cells through the myogenic lineage (53). Hierarchical expression of myogenic
regulatory factors Myf5, MyoD, and myogenin and embryonic/developmental isoform of
myosin heavy chain (eMyHC) is required for completing the myogenic program (53, 64). To
determine at which stage of myogenesis TRAF6 signaling in satellite cells is required, we
performed immunostaining for eMyHC, an isoform that is expressed by newly formed
muscle fibers. Regenerating muscle from TRAF6scko mice contained drastically reduced
number and smaller size eMyHC+ fibers (Figures 4.5A-C) compared to corresponding
TRAF6f/f at 3 and 5 days post-injury. Moreover, the mRNA levels of eMyHC were
significantly reduced in injured TA muscle of TRAF6scko mice compared to corresponding
TRAF6f/f mice (Figure 4.5D). Furthermore, transcript levels of Myf5, MyoD and myogenin
were also found to be significantly reduced in injured TA muscle of TRAF6scko mice
compared to injured TA muscle of TRAF6f/f mice (Figure 4.5E). Intriguingly, transcript
levels of Myf5 were also found to be significantly reduced in contralateral uninjured TA
muscle of TRAF6scko mice (Figure 4.5E) leading to conjure that TRAF6 has a pivotal role
in regulating the early stages of myogenesis in satellite stem cells.

TRAF6 is required for maintenance of satellite cell pool in skeletal muscle. The reduced
number and size of e-MyHC+ fibers accompanied with down-regulation of transcript levels
of myogenic regulatory factors in injured muscle of TRAF6scko mice suggest the possibility
of reduced number of activated satellite cells available to participate in the myogenic
program or an intrinsic defect in the satellite cells ability to progress through the myogenic
lineage to form fusion competent myoblasts. It has been unarguably evident that Pax7
expression is vital for maintaining satellite cell function (143, 144). A fundamental
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characteristic of adult stem cells is the ability to serve as source of tissue-specific
differentiated cells while retaining the capacity to self-renew and repopulate the stem-cell
niche. Such potential is inherent in muscle satellite cells by a timely regulated expression of
Pax7 (82, 142, 144). Quiescent satellite cells are Pax7+/MyoD- (84, 142). In response to
activating stimuli, satellite cells start expressing MyoD giving rise to proliferating myoblasts
(149, 155). Sustained expression of Pax7 alongside MyoD is essential for generating
adequate amount of myogenic progeny to drive proper muscle repair. Conditional
inactivation of Pax7 in adult mice led to defective muscle regeneration following injury and
progressive loss of the satellite cell pool due to premature differentiation of Pax7-null
satellite cells (144). To understand the role of TRAF6 in regulation of Pax7 expression in
satellite cells, muscle section from 5d saline or BaCl2-injected TRAF6scko and TRAF6f/f mice
were immunostained for Pax7 (Figure 4.6A). While injured muscle of TRAF6f/f
demonstrated efficient activation of satellite cells evident by a dramatic up-regulation in
Pax7+ cells, such increase was not observed in corresponding TRAF6scko muscle (Figures
4.6A, 4.6B). Strikingly, the number of Pax7+ cells was also significantly reduced in
contralateral uninjured muscle of TRAF6scko mice compared to that of TRAF6f/f mice
(Figures 4.6A, 4.6B). Consistent with reduced number of Pax7+ cells, we found that protein
and mRNA levels of Pax7 along with eMyHC protein were dramatically reduced in injured
TA of TRAF6scko mice compared with TRAF6f/f mice (Figure 4.6C, 4.6D). Moreover,
mRNA levels of Pax7 were also found to be significantly reduced in uninjured TA muscle of
TRAF6scko mice compared with TRAF6f/f mice (Figure 4.6D). To further clarify the role of
TRAF6 in satellite cells, we FACS analyzed satellite cells content in uninjured and 5d
injured TA muscle of TRAF6scko and TRAF6f/f mice using α7-integrin as a marker of
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satellite cells and excluding CD31, CD45, Sca1, and Ter119+ populations (Figure 4.6E).
Consistent with immunohistological results, TA muscle of TRAF6scko demonstrated a
modest up regulation in α7-integrin+ cells following injury compared to that of TRAF6f/f
mice (Figures 4.6E, 4.6F). Furthermore, number of α7-integrin+ cells was found to be
reduced in uninjured muscle of TRAF6scko mice compared with corresponding TRAF6f/f
mice (Figure 4.6F).
We also measured the transcript levels of a few target genes of Notch pathway, a
known regulator of satellite cell dynamics in both quiescent and activated states (57, 72, 73).
Notably, mRNA levels of Hey, HeyL, Hes1, and Hes6 were significantly reduced in injured
muscle of TRAF6scko mice (Figure 4.7). It has been reported that Hes1 and HeyL are
involved in maintaining the quiescent status of satellite cells (72). Interestingly, we found
that the transcript levels of HeyL and Hes1 were diminished in uninjured muscle of
TRAF6scko compared to uninjured muscle of TRAF6f/f mice (Figure 4.7). These results
suggest that TRAF6 is required the maintenance of satellite stem cell pool and their function
in vivo.

Ablation of TRAF6 inhibits satellite cell self-renewal and causes premature
differentiation. We next investigated dynamics of TRAF6-null satellite cells in cultures.
Single myofibers were established from EDL muscle of TRAF6f/f and TRAF6scko mice and
the satellite cells associated with them were analyzed immediately or 72h after culturing.
Consistent with our in vivo results, a substantial reduction in the number of quiescent Pax7+
satellite cells was clearly noticeable in freshly isolated fibers of TRAF6scko mice (Figures
4.8A, 4.8B). Intriguingly, the majority of Pax7+ cells associated with TRAF6scko myofibers

102

were also expressing MyoD (Figures 4.8A, 4.8B). Corresponding fibers from TRAF6f/f
mice contained an average of 6 satellite cells that were predominantly Pax7+/MyoD- (Figure
4.8C). The reduced number of Pax7+ satellite cells on freshly isolated myofibers of
TRAF6scko mice and the untimely expression of MyoD implies a pre-mature inclination of
TRAF6-null satellite cells towards entering the cell cycle and failure to self-renew.
To further understand the myogenic potential of TRAF6-deficient satellite cells,
myofibers and associated cells were fixed after 72h in suspension culture and
immunostained for Pax7 and MyoD. Myofiber-associated TRAF6f/f satellite cells displayed a
normal activation profile characterized by formation of satellite cell clusters and normal
distribution of self-renewing (Pax7+/MyoD-), proliferating (Pax7+/MyoD+), and
differentiating (Pax7-/MyoD+) cells (Figures 4.8D-F). However, myofibers from TRAF6scko
mice exhibited scattered distribution of singlet and couplet cells and no evident clusters
originating from a single clone (Figures 4.8D-F). Moreover, majority of cells were Pax7/MyoD+ and a few cells that were Pax7+ were unanimously MyoD+ with diminished
expression of both proteins (Figures 4.8D-F).
We also investigated whether deficiency of TRAF6 also compromises the fusion
potential of myogenic cells. Primary myoblasts prepared from TRAF6f/f and TRAF6scko mice
were plated at high density and differentiation was induced through serum withdrawal
TRAF6-deficient myoblast were capable of fusion evident by normal myotube formation
(Figure 4.9). These results suggest that TRAF6 is required for self-renewal and maintaining
the myogenic potential of satellite cells.
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TRAF6 mediates proliferation and gene expression of Pax7 in satellite cells. Lack of
satellite cell clusters on culture myofibers of Traf6scko mice indicates a requirement of
TRAF6 for maintaining satellite cells’ replicative capacity. To directly address this issue, we
prepared primary myoblasts from hind limb muscle of C57BL6 mice and transfected them
with vector alone (pcDNA3), full length TRAF6 (TRAF6-FL), or a dominant negative (DN)
mutant of TRAF6 (TRAF6-DN). The number of satellite cells was measured after Pax7
staining whereas cellular proliferation was studied by EdU incorporation. Interestingly,
forced expression of TRAF6-FL significantly increased the number of Pax7+ cells (Figures
4.10A, 4.10B) and the incorporation of EdU in myoblast cultures (Figure 4.10C). By
contrast, number of Pax7+ or EdU+ cells was significantly reduced in the cultures transfected
with TRAF6-DN (Figures 4.10A-C).
To determine whether TRAF6 is required for the gene expression Pax7 in satellite
cells, we measured the transcript levels of Pax7 in myoblast cultures transfected with
TRAF6-FL or TRAF6-DN. Interestingly, forced expression of TRAF6-FL had no effect on
Pax7 mRNA levels whereas the cells transfected with TRAF6-DN exhibited a significant
reduction in mRNA levels of Pax7 (Figure 4.10D). We also investigated the effects of
knockdown of TRAF6 on mRNA levels of Pax7. Results showed that shRNA-mediated
knockdown of TRAF6 significantly reduced the mRNA levels of Pax7 in primary myogenic
cultures (Figure 4.10E). These results give rise to two possibilities: (a) TRAF6 regulates the
proliferative capacity of Pax7+ cells with no direct effect on the gene expression on Pax7, or
(b) TRAF6 is a signaling intermediate through which upstream molecular configurations
lead to the activation of Pax7 locus and hence the forced expression of TRAF6 in isolation
of a parallel overexpression of a docking molecule does not increase the gene expression of
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Pax7. To address this issue, we studied the effects of interleukin-1β (IL-1β) on the levels of
Pax7 and cellular proliferation. In response to IL-1β, TRAF6 is recruited to the IL-1 receptor
(IL-1R) serving as a scaffold protein which lead to the activation of downstream signaling
molecules (101). Therefore, we postulated if TRAF6 is the liaison for a higher hierarchal
interaction that initiates downstream expression of Pax7, stimulation of such pathway should
lead to the increased gene expression of Pax7 in satellite cells. Indeed, primary myoblasts
treated with IL-1β displayed a dramatic up-regulation in levels of Pax7 protein (Figure
4.10F). Intriguingly, IL-1β did not affect the levels of TRAF6 in satellite cells (Figure
4.10F) further confirming that TRAF6 is a possible transducer of a signaling pathway that
leads to the increased expression of Pax7 in satellite cells. Moreover, cells treated with IL1β displayed enhanced replicative capacity evident by increased EdU incorporation (Figures
4.10G, 4.10H). Collectively, these findings imply that TRAF6 is an integral component of a
pathway that is required for the gene expression of Pax7 and proliferation of satellite cells.

TRAF6 regulates the expression of Pax7 in satellite cells through activation of ERKs
and JNK. Recently, signaling from MAPKs has been linked to various stages of satellite
cell-cycle regulation. ERK1/2-mediated signaling in satellite cells promoted a G0-like
phenotype (152) while signaling through p38 MAPK stimulated their activation and terminal
differentiation (102, 156). Functional outcome of either pathway has been shown to take
place through direct or indirect regulation of Pax7 expression (152, 156). Our attempts to
directly isolate primary myoblasts from skeletal muscle of tamoxifen-treated
TRAF6scko mice were unsuccessful due to reduced number of myofiber-associated satellite
cells in these mice and failure of the cells to grow in culture upon seeding. We then isolated
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satellite cells from hind limb muscle of non-tamoxifen treated TRAF6scko mice and
expanded them in the cultures followed by treatment with vehicle alone or 4hydroxytamoxifen (4-OHT) to induce tamoxifen-mediated Cre recombination. Treatment
with 4-OHT drastically reduced the protein levels of TRAF6 in myoblast cultures (Figure
4.11A). Consistent with in vivo results, a substantial reduction in Pax7 protein levels was
noticeable in TRAF6scko cultures treated with 4-OHT compared to those treated with vehicle
alone (Figure 4.11A). Interestingly, phosphorylation levels of ERK1/2 and JNK1/2 were
considerably reduced while no such effect was observed on ERK5 phosphorylation (Figure
4.11B). The reduction in ERK1/2 phosphorylation is in line with previously published
reports indicating the involvement of ERK1/2 pathway in regulating proliferation and selfrenewal of satellite cells in a context-dependent manner (152, 157, 158). Intriguingly,
ablation of TRAF6 using 4-OHT drastically increased the levels of p38 phosphorylation
(Figure 4.11B) aligning with a role of p38 in promoting progression through the myogenic
lineage (102, 159). More importantly, total and phosphorylated levels of c-Jun, a direct
phosphorylation target of ERK1/2 and JNK (160), were also diminished as a result of
deletion of TRAF6 (Figure 4.11C). IL-1which increases the levels of Pax7, also
increased the phosphorylation of c-Jun in satellite cell cultures (Figure 4.11D).
Furthermore, we also found that in vivo ablation of TRAF6 in satellite cells (i.e. tamoxifentreated TRAF6scko) reduced the phosphorylation of c-Jun in injured skeletal muscle of mice
(Figure 4.11E).
To understand the direct role of various MAPK pathways in Pax7 expression,
primary myoblasts prepared from WT mice were treated with specific MAPK inhibitors:
PD184352 which inhibits ERK1/2, SP6100125 which inhibits JNK, and SB203580 which
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inhibits the p38MAPK pathway. After 48 hours of treatment, mRNA and protein levels of
Pax7 were measured. Interestingly, cells treated with ERK1/2 or JNK inhibitors significantly
reduced mRNA and protein levels of Pax7 while those treated with p38 inhibitor had no
effect on Pax7 expression (Figure 4.11F). Furthermore, cells treated with ERK1/2 and JNK
inhibitors (but not p38 inhibitor) exhibited a sharp decrease in c-Jun phosphorylation
(Figure 4.11G). To understand the role of c-Jun in regulation of Pax7 expression, we
performed loss-of-function and gain-of-function experiments. In correlation with the
preceding findings, shRNA-mediated knock down of c-Jun sharply reduced the levels Pax7
mRNA in primary myoblast cultures from WT mice (Figure 4.11H). By contrast,
overexpression of c-Jun significantly increased the mRNA levels of Pax7 in myoblast
cultures (Figure 4.11I). Notably, c-Jun is known to form homo- or hetro- dimers with other
Jun or Fos family members giving rise to AP1 transcription factor (161). Since c-Jun
possesses a transactivation domain, we contemplated that c-Jun regulates Pax7 expression
through direct binding of Pax7 promoter. Our in silico analysis of 3.5 kb region upstream of
transcription start site in Pax7 promoter revealed 11 potential consensus sequence for
AP1/c-Jun transcription factor (data not shown). To understand whether c-Jun enrich the
Pax7 promoter, we performed chromatin immunoprecipitation (ChIP) assay. Intriguingly, 4
out of 11 potential sites displayed high enrichment in Pax7 promoter in primary myoblasts
(Figure 4.11J). All together, these findings demonstrate that TRAF6-mediated signaling
augments Pax7 levels through the activation ERK1/2 and JNK which in turn activate c-Jun
transcription that directly interacts with the promoter region of Pax7.
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Ablation of TRAF6 augments the levels of muscle-specific microRNAs (myomiRs) in
satellite cells. MicroRNAs are a class of short (19-22 bp) non-coding RNAs that function as
post-transcriptional regulators of gene expression (162). By hybridizing to complimentary
binding sites in the 3′ untranslated region (UTR) of target mRNAs, miRNAs inhibit protein
translation through mRNA cleavage or steric hindrance (162-164). Recently, a group of
muscle specific miRNAs (MyomiRs) consisting of mir-1, miR-206 (163-165), miR-133a,
and miR-133b has been shown to be critical in regulating skeletal muscle development.
Expression levels of miR-1, miR-206 and miR-133 were found to be sharply upregulated
during myogenesis (164). Furthermore, miR-1 and miR-206 have been shown to promote
satellite cell differentiation through direct targeting of Pax7 mRNA (148). To investigate if
TRAF6 also regulates Pax7 abundance in a microRNA-mediated manner, we measured the
levels of miR-1, miR-206, and miR-133a in TRAF6-deficient primary myoblasts. Strikingly,
expression levels of all three miRNAs were found to be dramatically increased upon
ablation of TRAF6 (Figure 4.12A). Since our preceding findings draw a possible role of cJun in mediating TRAF6 regulation of Pax7 transcription, we further delineated weather
TRAF6-mediated regulation of MyomiRs is also brought about through a c-Jun dependent
mechanism. We found that overexpression of c-Jun repressed the levels of miR-206 and
miR-133a in cultured satellite cells (Figure 4.12B). Collectively, these results are suggestive
of a possible post-transcriptional role of TRAF6-MAPK-AP1 axis in mediating Pax7
expression.

Deletion of TRAF6 in satellite cells exacerbates myopathy in mdx mice. Functional
inactivation of the dystrophin gene is the primary cause of Duchenne muscular dystrophy
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(DMD) in humans and in mdx mice (a mouse model of DMD) (8). Dystrophic muscle
undergoes repetitive rounds of degeneration and regeneration (8, 14). To further examine the
role of TRAF6-mediated signaling in satellite cells, we investigated the effects of ablation of
TRAF6 in satellite cells of mdx mice on myopathy. TRAF6scko mice were crossed with mdx
mice to generate mdx;TRAF6scko and littermate mdx;TRAF6f/f mice. In mdx mice, acute
muscle injury starts at around 2.5 weeks and peaks between the age of 3-4 weeks (14) after
which alternating cycles of regeneration and degeneration persists till the age of 12 weeks.
Accordingly, tamoxifen mediated Cre recombination was initialized at 3 weeks of age and
analysis was conducted at the age of 8 weeks. We found a significant decrease in size and
body weight of mdx;TRAF6scko mice compared with littermate mdx;TRAF6f/f mice (Figures
4.13A, 4.13B). Furthermore, mdx;TRAF6scko mice displayed reduced functional output
evident by decreased forelimb grip strength and total four-limb grip strength (Figure
4.13C). Wet weight of gastrocnemius (GA) and quadriceps muscles was also found to be
significantly reduced in mdx;TRAF6scko mice compared to littermate mdx;TRAF6f/f mice
(Figure 4.13D). Analysis of H&E-stained muscle sections of mdx;TRAF6scko mice showed
signs of exacerbated myopathy marked by increased necrotic areas and failure of
regeneration manifested by the lack of centronucleated fibers and exaggerated pseudomuscle hypertrophy (Figure 4.13E). Increased myopathy was also reflected by significantly
higher levels of creatine kinase (CK) in plasma of mdx;TRAF6scko mice compared to
mdx;TRAF6f/f mice (Figure 4.13F). Consistent with our findings in the BaCl2-mediated
model of injury, these results suggest that TRAF6 is required for satellite cell function in
dystrophic muscle.
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4.4 DISCUSSION
Under normal conditions Pax7 expressing satellite cells reside in quiescence beneath the
basal lamina of adult muscle (52). In response to activating stimuli such as injury, satellite
cells rapidly enter the cell cycle by up regulating MyoD giving rise to a population of
proliferating myoblasts (85, 155). The majority of activated satellite cells progress through
the myogenic lineage and undergo terminal differentiation leading to the forming new
mature muscle, while a subpopulation homes back to the muscle niche to replenish the
reservoir of satellite cells (85, 142). This process is driven by coordinated regulation of
intrinsic and extrinsic factors that culminate in controlling the expression status of Pax7
which in turn determines the fate of satellite cells (64, 70, 152). Thus, the precise regulation
of Pax7 is pivotal for maintaining satellite cell function in skeletal muscle.
Our findings in this study illustrate a satellite cell autonomous role of TRAF6 in
regulating Pax7 function in adult skeletal muscle. Conditional deletion of TRAF6 in satellite
cells led to defective muscle regeneration following BaCl2-mediated injury (Figures 4.3,
4.4). Satellite cells from regenerating muscle of TRAF6scko mice failed to provide sufficient
competent myogenic cells capable of driving proper regeneration program (Figure 4.6).
Diminished number of activated Pax7+ cells led to inadequate muscle formation evident by
reduced number and size of eMyHC+ fibers upon deletion of TRAF6 (Figure 4.5).
Failure of TRAF6-KO satellite cells to drive proper regeneration could be attributed
to: (a) failure in activation and exiting quiescence, (b) proper activation and entry to the cell
cycle but impaired replicative capability, (c) proper activation and proliferation capacities
but fusion incompetency, (d) improper activation and proliferation but fusion competency,
or (e) improper activation and proliferation associated with fusion incompetence. Excluding
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(c), reduced number of activated Pax7+ satellite cells in regenerating muscle of
TRAF6scko mice (Figure 3) gives rise to any of the remaining possibilities. Nevertheless,
decreased expression of Pax7 and reduced number of Pax7+ satellite cells in sham muscle
(Figure 4.6) and freshly isolated myofibers of TRAF6scko mice accompanied with MyoD
expression (Figure 4.8) also rules out the first possibility, as abetment of Pax7 expression
indicates loss of quiescence and upregulated MyoD levels implies activation. Furthermore,
lack of cell cluster formation associated with cultured TRAF6scko myofibers (Figure 4.8)
and reduced EdU incorporation in DN-TRAF6 transfected myoblast (Figure 4.10) are direct
evidence for elimination of probability (b), leaving the possibility of (d) or (e). However,
normal myotube formation displayed by TRAF6-KO myoblasts plated at high confluency
(Figure S5) indicates preserved fusion capacity giving strong plausibility to the
interpretation in (d). Our systematic examination of the expression profile and activation and
proliferation dynamics implicates loss of myogenic lineage upon deletion of TRAF6 due to
deregulation of Pax7 expression, which in turn leads to precocious differentiation.
Our results further demonstrate that TRAF6 regulates Pax7 expression in a context
dependent manner. While knockdown of TRAF6 considerably reduced the mRNA levels of
Pax7 (Figures 4.10D, 4.10E), over expression of TRAF6 alone had no effect on Pax7
transcription (Figure 4.10D). Forced activation of TRAF6-mediated signaling by treatment
with IL-1 enhanced the expression levels of Pax7 with no notable effect on TRAF6 levels
(Figure 4.10G). These findings led us to contemplate that TRAF6 is an essential mediator of
upstream signaling that regulates downstream expression of Pax7 and that loss of TRAF6mediated signaling transduction brings halt to the Pax7 activating pathway.
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Moreover, our study indicates that TRAF6 regulates Pax7 function of satellite cells
through conditional activation and deactivation of specific MAPK family signaling
pathways (Figure 4.11). Increased expression of p38 MAPK in TRAF6-KO myoblasts
(Figure 4.11B) lends further support to the premise that loss of TRAF6 in myogenic cells
leads to precocious differentiation. Signaling from p38MAPK has been shown to play an
essential role in regulating the later stages of myogenesis (156, 166). Quiescent satellite cells
treated with p38 inhibitors failed to enter the cell cycle upon induction of activation. In
contrast, overexpression of p38 promotes exit from quiescence and premature induction of
terminal differentiation (156, 159). Conversely, phosphorylation levels of ERK1/2 were
dramatically reduced in TRAF6-KO cells (Figure 4.11B) consistent with the published role
of ERK1/2 signaling in regulating proliferation and self-renewal of satellite cells in a
context-dependent manner (152, 157, 158). Additionally, our results implicates a parallel
role of JNK signaling in regulation of satellite cells, as phosphorylated JNK protein levels
were also reduced upon deletion of TRAF6 (Figure 4.11B) and inhibition of JNK
independently reduced Pax7 expression levels mirroring ERK1/2 inhibition (Figures 4.11F,
4.11G). Of note, JNK signaling has been shown to counteract p38 activity; therefore it is
possible that reduced JNK signaling brought about by deletion of TRAF6 leads to
hyperactivation of p38 signaling in satellite cells which in part promotes exit from
quiescence and precocious differentiation. Our findings also suggest that Pax7 regulation
through ERK1/2 and JNK signaling takes place in a c-Jun dependent manner.TRAF6-KO
primary myoblasts exhibited a dramatic reduction in total and phosphorylated levels of c-Jun
protein (Figure 4.11C) and inhibition of ERK1/2 and JNK pathways similarly reduced
phosphorylation of c-Jun in WT myoblasts (Figure 4.11F). Importantly, cells knocked-
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down of c-Jun displayed a phenotypic outcome that resembled that of TRAF6-KO myoblast
(Figure 4.11H). Our ChIP data further validates the inference that TRAF6 regulates gene
expression of Pax7 in myoblasts through direct binding of c-Jun to multiple sites in the
mouse Pax7 promoter (Figure 4.11J).
Interestingly, our findings further suggest a potential post transcriptional role of cJun in modulating Pax7 levels. Pax7 has been identified as one of the direct regulatory
targets of miR-1 and miR-206 (148), both of which were found to be upregulated in TRAF6KO myoblasts (Figure 4.12A) and diminished upon c-Jun overexpression (Figure 4.12B).
However, further investigations will be required to determine whether the alterations
observed in MyomiRs are mere phenotypic outcomes or possible auxiliary regulatory facets
that modulate Pax7 expression in TRAF6 context.
The role of TRAF6 in regulating satellite cell function is further supported by our
findings in the mdx mouse (Figure 4.13). In resemblance to various injury models, satellite
cells drive the events of muscle regeneration in dystrophic muscle. Deletion of TRAF6 in
satellite cells of mdx mice led to exacerbated myopathy as a result of impaired regeneration
(Figure 4.13). Exhaustion of satellite cell myogenic capacity accompanies progression of
dystrophinopathy leading to cessation of muscle regeneration. Although therapies aimed at
improving the muscle microenvironment have demonstrated to be transiently advantageous,
extensive investigations have shown that premature loss of satellite cell function in
dystrophic muscle is due to a cell autonomous defect. Modulating TRAF6 levels in satellite
cells of dystrophic muscle or donor cells may prove to be beneficial in prolonging the
myogenic potential and replenishing the reservoir of satellite cells.
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In summary, our present study has identified a previously unrecognized role of
TRAF6 in regulation satellite cell function. TRAF6-mediated regulation of satellite cells to
takes place through regulating the expression of Pax7. TRAF6 is also necessary to
maintaining the quiescent state of satellite cells under unchallenged conditions, sustaining
the myogenic potential upon stimulation, and regulating self-renewal following activation.
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FIGURE 4.1

FIGURE 4.1. Generation of conditional satellite cell-specific TRAF6-knock out
(TRAF6scko) mice. (A) Schematic illustration of the breeding strategy to obtain TRAF6scko
and littermate TRAF6f/f mice. (B) Representation of the time line of tamoxifen mediated
Cre-recombination. (C) Representative immunoblot displaying TRAF6 protein levels in
injured and naïve TA muscle 5 days post BaCl2 injection following Cre-recombination.
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FIGURE 4.2
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FIGURE 4.2. TRAF6 is expressed in satellite cells. Primary myoblasts were isolated from
hind limb muscle of BL6 mice and FACS sorted based on 7-Intigrin expression. (A)
Representative dot plot displaying enrichment of TRAF6+ cells amongst a7-intigrin+
population. (B) Primary myoblast seeded in matrigel coated plates were fixed and labeled
with antibodies that recognize TRAF6 and Pax7. Representative photomicrograph
illustrating co-localization of TRAF6 and Pax7 in mouse primary myoblasts are presented
here. In a separate experiment primary myoblasts were induced to differentiate by serum
withdrawal for various time points after which protein extracts were prepared (C)
Representative immunoblots demonstrating regulation of TRAF6, Pax7, and MyHC levels
during myogenesis.
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FIGURE 4.3
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FIGURE 4.3. TRAF6 is required for skeletal muscle regeneration. Following tamoxifenmediated Cre recombination, TA muscle of adult TRAF6f/f and TRAF6scko mice were
injected with 100l of 1.2% BaCl2 solution after which muscles were isolated and analyzed
at different time points. (A) Representative photomicrographs of H&E-stained sections
illustrating a severe regeneration defect in injured muscle of TRAF6scko mice compared with
TRAF6f/f littermates. Quantification of (B) number of centrally nucleated fibers (CNF) per
unit area (C) number of myofibers containing more than one central nuclei and (D) Cross
sectional area (CSA) of centrally nucleated fibers 5d post BaCl2-mediated injury. Error bars
represent SD. N=3 in each group. *p < 0.05 vs. saline injected TA muscle TRAF6f/f mice and
#p<0.05 vs. saline injected TA muscle of TRAF6scko mice.

119

FIGURE 4.4
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FIGURE 4.4. Loss of muscle tissue following double injury in TRAF6scko mice. TA
muscle of TRAF6scko and TRAF6f/f mice were subjected to a first BaCl2 injection and
injured muscles were allowed to heal for 21 days after which a second round of muscle
injury was induced and muscle regeneration was analyzed 5 days following the second
BaCl2 injection. (A) Representative photomicrograph of H&E stained TA muscles of
TRAF6scko and TRAF6f/f mice. (B) Representative photo micrograph of trichrome-stained
TA muscle of TRAF6scko and TRAF6f/f mice.
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FIGURE 4.5
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FIGURE 4.5. Ablation of TRAF6 in satellite cells inhibits formation of new myofibers
(eMyHC+) following injury. (A) Representative photomicrograph of eMyHC-stained
sections prepared from TA muscle of TRAF6f/f and TRAF6scko mice collected at various time
points following BaCl2 injection. (B) Number and (C) CSA of eMyHC+ fibers are presented
here. In a separate experiment, TA muscle of TRAF6f/f and TRAF6scko mice were injected
with 1.2% BaCl2 or saline. After 3 days, the TA muscle was isolated and processed for qRTPCR. Relative mRNA levels of (D) eMyHC and (E) Myf5, MyoD, and myogenin are
presented here. Error bars represent SD. n=3 in each group. * p < 0.05 vs. saline injected
TRAF6f/f muscle and #p<0.05 vs. saline injected TRAF6scko muscle.
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FIGURE 4.6

124

FIGURE 4.6. TRAF6 is required for maintenance of satellite cell pool in skeletal
muscle. TA muscle of TRAF6f/f and TRAF6scko mice were injected with 1.2% BaCl2 or
saline for 5days after which muscles were isolated and processed for histological and
biochemical analysis. (A) Representative photomicrographs of Pax7-stained sections. Nuclei
were identified by co-staining with DAPI. Arrows point to Pax7+ cells. (B) Quantification of
average number of Pax7+ cells per myofiber in BaCl2 and saline injected muscle of TRAF6f/f
and TRAF6scko mice. (C) mRNA, and (D) protein levels of Pax7 are presented here. (E)
Representative FACS dot plots demonstrating the percentage of a7-integrin+ cells in saline
and BaCl2 injected TA muscle of TRAF6f/f and TRAF6scko mice. (F) Quantification of a7integrin+ satellite cells in saline- or BaCl2-injected TA muscle of TRAF6f/f and
TRAF6scko mice by FACS. Error bars represent SD. N=3 or 4 in each group. *p < 0.05 vs.
saline injected TRAF6f/f muscle. #p<0.05 vs. saline injected TRAF6scko muscle.
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FIGURE 4.7.

FIGURE 4.7. Notch signaling is compromised in skeletal muscle of TRAF6scko mice. TA
muscle of TRAF6scko and TRAF6f/f mice were injured with BaCl2 injection and 3days later
muscles were collected and processed for qRT-PCR analysis. Representative bar diagrams
illustrating relative mRNA levels of Notch pathway target genes in naive and injured TA
muscles of TRAF6scko and TRAF6f/f mice. Error bars represent SD. N=3 in each group. *p <
0.05 vs. saline injected TRAF6f/f muscle and #p<0.05 vs. saline injected TRAF6scko muscle.
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FIGURE 4.8
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FIGURE 4.8 Deletion of TRAF6 in satellite cells leads to premature differentiation.
Single myofibers were isolated from EDL muscle of TRAF6f/f and TRAF6scko mice. At 0h
and 72h of culture, myofibers were collected and labeled with antibodies against Pax7 and
MyoD. Nuclei were counter stained with DAPI. (A) Representative merged images of
freshly isolated myofibers from TRAF6f/f and TRAF6scko mice stained with Pax7, MyoD and
DAPI. Quantification of number of (B) Pax7+/MyoD- and (C) Pax7+/MyoD+ cells per fiber
are presented here. (D) Representative merged images of myofibers isolated from TRAF6f/f
and TRAF6scko mice after 72h of suspension culture. Bar histograms representing (E)
number of cells per cluster and (F) percentage of self-renewing Pax7+/MyoD- cells per
myofibers following 72h of culture. Error bars represent S.D. *, p < 0.05, values
significantly different from TRAF6f/f myofibers.
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FIGURE 4.9

FIGURE 4.9. Fusion capacity is preserved in TRAF6 deficient myoblasts. Primary
myoblast were prepared from hind limb muscle of non-tamoxifen administered TRAF6scko
mice. Following purification, cells were treated with vehicle or 10ng/ml 4-OHT to induce
Cre-recombination. 7 days post 4-OHT treatment, cells were plated at high density and
induced for differentiation via serum withdrawal. Photomicrograph of vehicle and 4-OHT
treated myoblasts stained with MF-20 at various time points of differentiation.

129

FIGURE 4.10
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FIGURE 4.10. TRAF6 axis is required for regulating Pax7 function in satellite cells.
Primary myoblasts were transfected with vector alone (pcDNA3) or plasmids containing full
length TRAF6 (TRAF6-FL) or dominant negative TRAF6 (TRAF6-DN) cDNA. Following
72h, cells were pulsed with EdU for 90 minutes after which cells were fixed and Pax7+ cells
were analyzed for EdU incorporation. (A) Representative photomicrograph of transfected
primary myoblasts labeled with Pax7 anti body and DAPI. Quantification indicates (B)
number of Pax7+ cells and (C) percentage of EDU+ cells to total nuclei. Error bars represent
S.D. * p < 0.05 vs. pcDNA3 transfected cells. #p<0.05 vs. Wt-TRAF6 transfected cells. (D)
In a separate experiment, cells were collected and processed for qRT-PCR. Relative levels of
Pax7 mRNA were quantified (E) Primary WT myoblasts were transfected with scramble
shRNA or TRAF6 shRNA and Pax7 transcription levels were measured * p < 0.05 vs.
scramble shRNA transfected cells. To elucidate the role of TRAF6-mediated IL-1β pathway,
primary myoblasts were treated with 10 ng/ml recombinant IL-1protein and after 24h cells
were processed for biochemical analysis. (F) Representative immunoblot labeled with Pax7
and TRAF6 antibodies. (G) In a separate experiment cells treated with IL-were pulsed
with EdU for 90 minutes and EdU incorporation in Pax7+ cells was analyzed. (H)
Quantification of percentage of EdU+ cells per number of nuclei is presented. Error bars
represent S.D. * p < 0.05 vs. vehicle treated myoblasts.
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FIGURE 4.11.
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FIGURE 4.11. TRAF6 regulates Pax7 function in satellite cells potentially through
MAPK singling. Primary myoblasts isolated from lower limb muscle of TRAF6scko mice
were treated with 4-OHT or vehicle. After 10 days in culture cells were collected and
processed for western blotting. Representative immunoblots demonstrating (A) TRAF6 and
Pax7 levels following Cre-recombination, (B) Levels of phosphorylated and total MAPK
family signaling proteins, (C) Levels of phosphorylated and total c-Jun. (D) Protein extracts
were prepared from WT primary myoblasts treated with IL-at different concentrations
for 24h. Representative immunoblot of phosphorylated c-Jun is presented here. (E)
Representative immunoblot displaying phosphorylated c-Jun protein levels in injured and
non-injured TA muscle of TRAF6f/f and TRAF6scko mice. To understand the role of MAPK
signaling in regulating Pax7 expression, WT primary myoblasts were treated with various
MAPK-signaling inhibitors for 48h after which cells were processed for biochemical
analysis. Illustration of (F) Pax7 protein and (G) Pax7 mRNA levels are presented here. In a
separate experiment, primary myoblasts were transfected with control vector, c-Jun shRNA
or c-Jun cDNA for 72hours and Pax7 mRNA levels were measured as shown in (H) and (I)
respectively. (J) Enrichment of c-Jun at four putative sites in Pax7 promoter was confirmed
through ChIP assay. Error bars represent S.D. *, p < 0.05, values significantly different from
corresponding controls.
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FIGURE 4.12.

FIGURE 4.12. TRAF6 deletion augments the levels of muscle-specific microRNAs
(MyomiRs) in satellite cells. Primary myoblasts isolated from lower limb muscle of nontamoxifin treated TRAF6scko mice were treated with 4-OHT or vehicle. After 10 days in
culture cells were processed for miRNA analysis. (A) Representative bar diagrams
illustrating expression levels of miR-1, miR-206 and miR-133a in 4-OHT and vehicle
treated TRAF6scko myoblasts. (B) WT primary myoblasts were transfected with vector alone
(pcDNA3) or c-Jun cDNA and 72h later expression levels of miR-206 and miR-206 were
quantified. *p < 0.05, values significantly different from corresponding controls.
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FIGURE 4.13.
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FIGURE 4.13. Depletion of TRAF6 in satellite cells exacerbates myopathy in mdx
mice. TRAF6scko mice were crossed with mdx mice and progression of dystrophinopathy
was analyzed at the age of 8weeks. (A) Body size and (B) weight of mdx;TRAF6scko and
TRAF6f/f mice are presented here. (C) Functional output was evaluated in mdx;TRAF6scko by
performing four-limb grip strength and total-limb grip strength tests. (D) Bar diagrams
representing wet weight of TA, GA, and quadriceps muscle of TRAF6f/f and TRAF6scko
mice. (E) Representative photomicrograph of H&E-stained GA muscle of 8-week old
TRAF6f/f and TRAF6scko mice are presented here. (F) Relative fold change in CK activity in
serum of 8-week old TRAF6f/f and TRAF6scko mice. Error bars represent S.D. N=4 in each
group. *, p < 0.05, values significantly different from TRAF6f/f mice.
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CHAPTER 5

CONCLUSIONS AND FUTURE WORK

This chapter summarizes the work presented in this dissertation and discusses its
implications in understanding adult skeletal muscle regeneration. It also highlights the
significance of the findings obtained throughout this dissertation while acknowledging the
limitations in implementing such findings in future research.

5.1 Review of dissertation
Skeletal muscle constitutes a greatly adaptable cellular system. Such pliant capacity is
acquired by a regulated signaling network that emanates from the differentiated muscle
fibers, the mitotic satellite cells, and the resident and infiltrating immune cells that populate
the muscle microenvironment. Through systematic examination of upstream signaling
regulator TRAF6, the findings of this dissertation accentuate the complexity of the
molecular events that take place in restoration of muscle homeostasis. Our investigations
revealed that TRAF6 mediates diverse functional outcomes at various stages of postnatal
myogenesis.
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As discussed in Chapter 2, deletion of TRAF6 in differentiated muscle (TRAF6mko)
enhanced muscle regeneration following acute injury through modulating the inflammatory
profile of the injured muscle microenvironment. Lack of TRAF6 signaling emitting from
muscle fibers attenuated the activation of NF-B pathway and promoted the induction of
pro-regenerative molecules (i.e. IGF-1 and IL-4) which neutralized the effect of various
inflammatory cytokines such as TNF- and IL-1Our findings revealed thatthe mitigated
inflammatory response brought about by deletion of TRAF6 augmented the conversion of
pro-inflammatory M1-macrophages into pro-regenerative M2-macrophages leading to
accelerated regeneration. Our findings further revealed that TRAF6 signal from
differentiated muscle antagonizes Notch signaling in satellite cells in a non-cell autonomous
manner as regenerating muscle of TRAF6mko mice displayed heightened activation of Notch
signaling which enhanced the myogenic potential of satellite cells in driving the
regeneration program.

The findings in Chapter 2 portrayed TRAF6 signaling as a promising molecular target in
combating various acquired and genetic myopathies. Along those lines, we contemplated in
Chapter 3 that abrogation of TRAF6 signaling from differentiated myofibers in dystrophic
muscle of mdx (model for Duchene muscular dystrophy) mice would similarly pacify the
inflammatory environment and improve muscle regeneration. Indeed, signs of
dystrophinopathy were greatly diminished in 8-week old mdx mice upon deletion of
TRAF6. mdx;TRAF6mko mice preserved muscle integrity evident by decreased CK activity
in blood serum and enhanced muscle regeneration on histological analysis. However,
examination in 9-month old mdx; TRAF6mko mice revealed exacerbated symptoms of mdx
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pathology manifested by increased muscle necrosis and inflammatory infiltration
accompanied by fibrotic tissue accumulation. Our investigations showed that exaggerated
myopathy in muscle of mdx;TRAF6mko mice is potentially due to reduced autophagy which
is known to be downstream of TRAF6 signaling. Impaired autophagic flux responsible for
clearing out cellular debris is associated with progression of dystrophinopathy and was
shown by our results to be further impaired as a result of deletion of TRAF6.

The focus of Chapter 4 was to understand the role of TRAF6 signaling in satellite cells of
adult skeletal muscle. Conditional deletion of TRAF6 under a tamoxifen-induced Pax7
promoter (TRAF6scko) led to deleterious muscle regeneration defects following induced and
myopathic muscle injury due to loss of satellite cell myogenic potential. The findings in this
chapter identified TRAF6 as a regulator of Pax7 function in satellite cells. TRAF6 was
shown to regulate Pax7 expression via downstream activation of ERK1/2 and JNK-MAPK
signaling pathways. Our findings further revealed that conditional MAPK regulation of Pax7
is a result of a direct binding of AP-1 transcription factor to the Pax7 promoter. In addition,
the study suggests a potential post-transcriptional role of AP-1 in regulating Pax7 expression
through modulating the levels of Pax7-targeting myomiRs.

Collectively, the results of this dissertation illustrate a multi-valent role of TRAF6 in
mediating the events of regenerative myogenesis. While deletion of TRAF6 in differentiated
muscle fibers enhanced muscle regeneration following acute injury, continued inhibition of
TRAF6 signaling was shown to be detrimental as evident by our investigations at the later
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stages of mdx pathology. Our findings further revealed an absolute requirement of TRAF6
in maintaining satellite cell function in adult skeletal muscle.

5.2 Contribution of dissertation and future implementations
Although the work presented in this dissertation underlines the role of a single signaling
transducer amongst a plethora of molecules that mediate the events of adult skeletal muscle
regeneration, the findings obtained serve broader implications. It has been clearly evident
that progression of myopathy is associated with aberrant activation of multiple signaling
cascades and modulation of such pathways has been perused as means of treatment.
However research strategies have been restricted to modulating single molecular axes,
which limited therapeutic potential. TRAF6 stands at a hierarchical advantage of several
signaling cascades which mediate deleterious outcomes. Thus, modulation of TRAF6
represents a promising strategy for collective modification of anomalous signaling, and as
result maximize alleviation. Our findings in the TRAF6mko mouse are testament for such
inference. Conversely, our findings in old mdx;TRAF6mko mice refute the same inference.
The results in Chapters 2 and 3 give rise to an intriguing line of pending examinations.
Exacerbated myopathy at the later stages of dystrophinopathy in mdx;TRAF6mko mice was
suggested to be a result of defective autophagy. Therefore, it would be of great interest to
delineate whether deletion of TRAF6 in differentiated myofibers combined with forced
activation of autophagy through a low protein diet would extend the beneficiary effects of
ablated TRAF6 signaling. Such therapeutic strategies might prove beneficial in treating
various acquired and genetic muscle disorders.
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On contrary lines, sustained TRAF6 signaling was shown to have a positive role in satellite
cells. Satellite cell myogenic potential is greatly compromised in many disease states
including DMD and is a major cause of failed regeneration. Strategies aimed at improving
endogenous satellite cell function as well as donor cells’ myogenicity are center of
tremendous investigations. Enhanced TRAF6 signaling in resident and donor satellite cells
represents a potential means for prolonging/restoring myogenic potential.

This work has unveiled the downstream outcomes of TRAF6 signaling in the skeletal
muscle cellular system. However, it remains unclear whether the expression of TRAF6 in
differentiated myofibers verses satellite cells is driven by common molecular regulators or is
mediated through distinct signaling events. Precise delineation of such mechanisms
represents an area of forthcoming investigations.

5.3 Limitations of future implications
The dissertation concludes in identifying distinct roles of TRAF6 signaling at various stages
of muscle formation. In addition to the role of TRAF6 in mediating destructive molecular
outcomes, TRAF6 signaling is essential for maintaining normal biological functions
required for skeletal muscle homeostasis. While genetic engineering techniques have
allowed for conditional deletion or overexpression of molecules in lab mouse models, such
discriminatory modification is not yet attainable upon consideration for translational
research. Therefore pharmological inhibition of TRAF6 might ultimately lead to detrimental
effects due to compromising its physiological role in skeletal muscle and other cellular
systems. This warrants caution on developing various target-based therapies. Thus, pursuing
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a means of selective modulation represents yet another challenging but crucial upcoming
endeavor. Addressing the matters at mention would elevate the significance of the findings
acquired throughout this dissertation.
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APPENDICES
APPENDIX-1
Sequence of the primers used in QRT-PCR assay.

Gene name
TRAF6
Myh4
Notch1
Notch2
Notch3
Dll1
Dll4
Jagged1
Jagged2
Hes1
Hes6
Hey1
HeyL
Nrarp
Myh3
Myogenin
Igf1
TNF-α
IL-1
IL-4
IL-10
Pax7
-actin

Forward primer (5’-3’)
GCAGTGAAAGATGACAGCGTGA
CGGCAATGAGTACGTCACCAAA
CAGGAAAGAGGGCATCAG
GCAGGAGCAGGAGGTGATAG
GTCCAGAGGCCAAGAGACTG
ACTGTACTCACCATAAGCCGTGCA
CACTTGCCACGATCTGGAGAAT
AACAAAGCTATCTGCCGACAGG
TTGGTGGCAAGAACTGCTCAGT
GCACAGAAAGTCATCAAAGCC
GCCGGATTTGGTGTCTACAT
TGAATCCAGATGACCAGCTACTGT
CAGATGCAAGCCCGGAAGAA
TGGTGAAGCTGTTGGTCAAG
ACATCTCTATGCCACCTTCGCTAC
CATCCAGTACATTGAGCGCCTA
CTCAGACAGGCATTGTGGATGAGT
GCATGATCCGCGACGTGGAA
CTCCATGAGCTTTGTACAAGG
GGATGTGCCAAACGTCCTC
CAAGGAGCATTTGAATTCCC
CAGTGTGCCATCTACCCATGCTTA
CAGGCATTGCTGACAGGATG
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Reverse primer (5’-3’)
TCCCGTAAAGCCATCAAGCA
TCAAAGCCAGCGATGTCCAA
AGCGTTAGGCAGAGCAAG
GCGTTTCTTGGACTCTCCAG
CAGAAGGAGGCCAGCATAAG
TCAGCTCACAGACCTTGCCATAGA
TGCCCACAAAGCCATAAGGA
GGCTGATGAGTCCCACAGTAATTC
GCTGTCACAGATGCAGGAGAAGTT
TTGATCTGGGTCATGCAGTTG
TCCTGAGCTGTCTCCACCTT
TACTTTCAGACTCCGATCGCTTAC
ACCAGAGGCATGGAGCATCT
CTTGGCCTTGGTGATGAGAT
GGGTCTTGGTTTCGTTGGGTAT
GAGCAAATGATCTCCTGGGTTG
GGTCTTGTTTCCTGCACTTCCTCT
AGATCCATGCCGTTGGCCAG
TGCTGATGTACCAGTTGGGG
GAGTTCTTCTTCAAGCATGGAG
GGCCTTGTAGACACCTTGGTC
GGTGCTTGGTTCAAATTGAGCC
TGCTGATCCACATCTGCTGG

APPENDIX-2
LIST OF ABBREVIATIONS
ALS………………………………autophagy lysosome system
cDNA……………………………complimentary deoxyribonucleic acid
CK…………………………….....creatine kinase
CTX……………………………..cardiotoxin
Cre……………………………....cyclase recombinase
CSA……………………………..cross sectional area
DAPT…………………………… N-[2S-(3, 5-difluorophenyl)acetyl]-L-alanyl-2-phenyl-1,1dimethylethyl ester-glycine
DGC…………………………......dystrophin-glycoprotein complex
DM………………………………differentiations medium
DMEM…………………………..Dulbecco’s modified eagle medium
EMSA…………………………....electrophoretic mobility shift assay
MyHC……………………………myosin heavy chain
eMyHC…………………………..embryonic myosin heavy chain
MAPK……………………………mitogen associated protein kinase
ERK………………………………extracellular signal-regulated kinase
FGF……………………………….fibroblast growth factor
GA………………………………...gastrocnemius
GM………………………………..growth medium
H&E…………………………........hematoxylin and eosin
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IGF………….…………………….insulin like growth factor
IgG………………………………..immunoglobulin G
IFN………………………….……interferon gamma
IL………………………………….interleukin
JNK………………………………..c-Jun N-terminal kinase
LC3………………………………..microtubule-associated
mko………………………………..muscle specific knock out
scko……………………………….satellite cell-specific knock out
mTOR……………………………..mammalian target of rapmaycin
MMP………………………………matrix metalloproteinase
mRNA……………………………..messenger RNA
MuRF1……………………………muscle Ring-finger protein
NF- B…………….……………...nuclear factor kappa-B
NICD……………………………..notch intracellular domain
Pax7………………………………paired box protein 7
PCR……………………………….polymerase chain reaction
QRT-PCR………………………....quantitative real-time polymerase chain reaction
SD…………………………………standard deviation
shRNA…………………………….short hairpin RNA
TA…………………………………tibial anterior
TGF……………………………….transforming growth factor
TNF…………………………….…tumor necrosis factor
TNFR…………………………..….tumor necrosis factor receptor
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TRAF……………………….……..TNFR associated factor
Ub………………….....…………....ubiquitin
UPS………………………………..ubiquitin-proteasome system
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